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ABSTRACT 
Oligonucleotide therapy is an evolving field having shown fast and important developments 
in the last years. From genetics to metabolic, inflammatory, immunodeficiency diseases, 
cancer and viral infections the medical applications for this type of therapy are becoming 
broader every day. However, the major challenge for these therapies is still the delivery; thus 
new chemistries, as well as improved delivery vectors are needed. Equally, the lack of 
relevant reporter systems hampers the characterization and progress of these emergent 
“drugs.” 
This thesis work was aimed to address some of the gaps presented above. Thus, the 
introduction section starts with a brief overview of the gene therapy. It continues with an 
explanation of the oligonucleotide therapy strategies and technologies used for RNA and 
DNA targeting and ends with a clinical case for each approach. The methodology section 
explains the theoretical and practical aspects of the most relevant techniques in this study and 
the results section explain the rational and gives a brief presentation of the main results and 
conclusions for each paper.  
Paper I presents a new splice-switching approach for treating diseases by regulating proteins 
at the splicing level. The new principle was to convert the normal splice form to a natural, but 
less abundant and inactive, splice variant to treat hypercholesterolemia. Paper II shows the 
development and characterization of a new collection of reporter cell lines for splice-
switching. These reporter cell lines can serve as models for cell-type-specific screenings of 
different ON chemistries and delivery vectors. Paper III and IV demonstrate the development 
and characterization of a new nucleic acid chemical modification providing an oligomer with 
cell penetrating properties. Finally, in paper V a new mechanism for gene expression 
regulation at the genome level is presented. 
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1 INTRODUCTION 
1.1 GENE THERAPY – AN OVERVIEW OVER TIME 
 
In 1971, at least 1500 human diseases were accepted to be genetically driven [1]. For the 
majority, the molecular basis was unknown and, despite the progress in the biochemical 
characterization of human genetic diseases, only ninety-two were found to be associated with 
a genetically induced specific enzyme deficiency [2]. By that time, several scientific 
advances allowed for better understanding of the structure and function of DNA [3–5], 
synthesis of nucleotides [6–8], cellular uptake of proteins and DNA by endocytosis [1], and 
the ability to manipulate DNA in vitro.  
Gene therapy emerged then, as the idea “that correct exogenous DNA could be used to 
compensate the defective DNA in the patients with the genetic defect” [1,9,10]. Initially, it 
would involve approaches like the introduction of DNA either directly or by somatic cell 
fusion, transfer of genetic material by virus-like particles, infection with active or inactive 
virus containing genes, or infection with a viral nucleic acid [9]. However, concerns about 
unknown outcomes were strong, as proven in later years [1,11]. 
The following years came with significant developments [11] as infectivity improvement of 
adenovirus [12], the mammalian cells transfection of plasmids with calcium phosphate by 
Wigler et al. [13], and the first western blotting protocol [14]. But also a better understanding 
of RNA processing [15], the in vitro synthesis of the beta globin gene by Maniatis et al. [16],  
and the first hypothesis of messenger RNA (mRNA) splicing by Catterall et al. [17].  
In 1980, Cline and his colleagues made the first human study, re-infusing bone marrow cells 
transfected in vitro with plasmids containing the human globin gene in thalassaemia patients. 
The study gave rise to controversy and, in response, the Recombinant DNA Advisory 
Committee of the NIH created the Gene Therapy Subcommittee to regulate the application of 
molecular genetic tools for human use [11]. By 1981, the life cycle and transduction 
capabilities of the retrovirus were unravelled. Immediately, reports appeared describing 
techniques to increase the genetic information transferred by a retrovirus and the production 
of vectors with infection efficiency of 100% in human and mammalian cells [11]. The virus 
became “the vectors”. Quickly, numerous studies demonstrating that several cell types could 
be stably genetically corrected with retroviral vectors increased its applicability in several 
genetic diseases [11]. In 1989, the first human genetic engineering experiment was approved 
[18] and in 1990 Blaese et al. initiate a gene therapy protocol aiming to correct adenosine 
deaminase deficiency [11,19–21]. Nowadays, cancer is the most common disease treated by 
virus-mediated gene therapy, followed by monogenetic, cardiovascular and infectious 
diseases. In clinical trials, the retroviral and the adenoviral vectors are the gene transfer 
vectors most common, with adenovirus showing to be a very successful carrier for e.g. 
haemophilia and retinal diseases. [21].  
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Parallel to the virus-mediated gene therapies, the oligonucleotide (ON) therapies were also 
developing, but in a more discreet way, following and/or promoting molecular biology 
advances [22]. Differently from the virus approach, ONs are designed specifically to 
modulate gene expression through different mechanisms. All share the same principle: 
binding of a complementary ON sequence, by Watson-Crick base pair hybridization, to the 
specific target [23].  
The first antisense approach was described in 1978, by Stephenson et al. and Zamecnik et al., 
and consisted of translation inhibition of the Rous sarcoma viral RNA by a sequence 
complementary oligodeoxyribonucleotide [24,25]. It was followed in 1979 by the discovery 
of the ribonuclease H1 (RNase H1) specific cleavage of RNA/DNA duplexes [26]. This two 
reports proved that ON therapeutics could be applied not only as steric-blockers of RNAs (§ 
1.2.3) but also as inducers of its degradation by an enzymatic process (§ 1.2.2). From this 
point, we observed a boost in ON synthesis of new chemical analogues (Table 1, § 1.4), as 
well as protocols for solid-support [27] and automation synthesis of DNA- [28] or RNA- [29] 
ONs. 
 
Table 1 - Chronology of chemical nucleotide analogues related to this study.  
Year Chemical Modification Localization References 
1964 2ˊ-Fluoro Sugar [6,7] 
1966 Phosphorothioate Phosphate backbone [8] 
1969 2ˊ-O-methyl (2ˊ-OMe) Sugar [30] 
1989 
Phosphorodiamidate Morpholino Oligomer 
(PMO) 
Sugar and phosphate 
backbone 
[31] 
1991 Peptide Nucleic Acid (PNA) 
Sugar and phosphate 
backbone replaced 
[32] 
1998 Locked Nucleic Acid (LNA) Sugar [33,34] 
1999 2ˊ-O-(Carbamoylmethyl) Sugar [35] 
2002 Tricyclo-DNA 
Sugar and phosphate 
backbone 
[36] 
2003 2ˊ-O-[2-(Amino)-2-oxoethyl] Sugar [37] 
2015 2ˊ-O-(N-(aminoethyl)carbamoyl)methyl (AECM) Sugar [38] and Paper IV 
  3 
Equally, due to the need to improve ON cellular uptake, we witnessed the development of 
new non-viral vectors and techniques like liposomes, cationic lipids, covalent lipophilic 
attachments, poly(L-lysine) formulations, asialoglycoprotein conjugates, among others 
[39,40] (§ 1.5).  
The possibilities for ONs application were widening, and new mechanisms of action were 
proven. Respectively, through direct interaction with enzymes, receptors or transcription 
factors; by inhibition of RNA processing, including RNA structures and splicing [41,42]; 
inhibition of replication and transcription by binding to duplex DNA [32,43]; and translation 
arrest by binding to mRNA [39,44] (§ 1.2). 
In 1993, the first clinical trial Phase I was approved using a phosphorothioate ON 
complementary to p53 mRNA in patients with acute myelogenous leukaemia or 
myelodysplastic syndrome [22,45]. In the same year, Dominski and Kole reported the 
recovery of correct splicing in thalassemic precursor mRNA (pre-mRNA) with a 2ˊ-O-methyl 
(2ˊ-OMe) RNA antisense ONs [41], establishing the splice correction/switching approach (§ 
1.2.3.1). Equally, the mutagenesis in human cells mediated with triple helix-forming ONs 
(TFOs) was also reported [46,47] (§ 1.3.1). The following advances were the discovery of the 
RNA interference (RNAi) pathway in 1998 [48,49]; the identification of small interfering 
RNAs (siRNA) [50]; and the discovery that siRNAs can effectively reduce gene expression 
in many mammalian cell types [51–55] (§ 1.2.1). Soon, the ON technology characterised by a 
simple concept, rational design, relatively inexpensive cost, and supported by the first 
sequencing of the human genome in 2001 [56], became essential not only as tools to study 
gene function but also as therapeutic agents. 
From 2010, several protocols based on DNA double-strand break-enhanced homologous 
recombination [57] emerged [21,58,59]. In these methods, a site-specific cleavage of 
genomic DNA is required and can be catalysed by zinc finger nucleases (ZFNs) [60–62] or 
transcription activator-like effector nucleases (TALENs) [63–65]. Recently (2012), the gene 
editing was revolutionised by a novel technique, the clustered regularly interspaced short 
palindromic repeat (CRISPR)/CRISPR-associated protein (Cas)9 system [59,66–68].  
Currently, the ON therapeutic field accounts for more than 130 clinical trials listed on 
ClinicalTrials.gov, three approved antisense drugs (Vitravene™, Macugen™ and 
Kynamro™) [69], and several others under consideration for market approval in the United 
States and Europe [70]. 
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1.2 OLIGONUCLEOTIDE THERAPIES – RNA THERAPEUTICS 
 
Oligonucleotide (ON) therapies are broad, involving diverse mechanisms of action and type 
of targets (RNA and DNA). The focus of this sub-section includes RNA therapeutics and 
splice-modulating therapies. 
RNA therapeutics consist of small synthetic ONs, that target precursor messenger RNA (pre-
mRNA) and mRNA. Almost all coding and non-coding RNA sequences are prone to be 
modulated by synthetic nucleic acids [71]. Three main approaches, involving the binding of 
complementary ONs to target RNA through base pairing are known (Figure 1): RNA 
interference (RNAi) [48,72,73] (§ 1.2.1), antisense ONs [74] (§1.2.2) and steric-blocking 
ONs [75] (§ 1.2.3). While RNAi and antisense ONs induce the mRNA enzymatic 
degradation, steric-blocking ONs act also at the pre-mRNA level and hinder the access of the 
cellular machinery to RNA without degradation [71,76]. 
 
 
 
Figure 1: Mechanisms of action of ON Therapeutics. ON cellular uptake can be either 
“naked” or mediated by cationic liposomes or peptide nanoparticles. It can occur via 
endocytosis, pinocytosis or phagocytosis pathways, which results in an entrapment in the 
endosome. After release, normally by destabilisation of the endosomal membrane the ON 
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escapes to the cytoplasm where it can mediate mRNA degradation by siRNA-mediated 
cleavage or RNase H1 cleavage, block the translation, or move to the nucleus. Here, ON can 
either bind to the pre-mRNA inducing splice modulation; or bind to the genome to mediate 
transcription regulation or chromatin remodelling (binding as TFOs, strand invasion of the 
DNA duplex, and interaction with DNA secondary structures or heterochromatin). 
 
1.2.1 RNA interference 
RNAi is a natural cellular process, responsible for regulating gene expression and providing 
an innate defence mechanism against invading viruses and transposable elements [72]. It was 
discovered in Caenorhabditis elegans, after the delivery of an exogenous, double-stranded 
RNA (dsRNA) that induced the silencing of the homologous host mRNA [48].  
The mechanism that mediates gene silencing involves 1. Degradation of double-stranded 
RNA (dsRNA) by endoribonuclease Dicer into small interfering RNAs (siRNAs), consisting 
of dsRNA fragments of 21–22 nucleotides long. 2. Interaction of siRNAs with a multiprotein 
RNA-induced silencing complex (RISC). 3. Inside the RISC, the two siRNA strands detach. 
The sense strand is discarded, and the antisense or guide strand binds to mRNA. 4. When 
siRNA is fully complementary to its target, the endonuclease Argonaute-2 (Ago2, a 
component of the RISC) cleaves the mRNA 10 and 11 nucleotides downstream of the 5′ end 
of the antisense strand [77]. The RNAi pathway is active in the cytoplasm and the nucleus 
[78]. The stable complex between Ago2 and the trinucleotide repeat containing 6 (TNRC6) 
family paralogs is conserved in the nucleus and cytoplasm, but accessory proteins differ 
among them, as showed by Kalantari et al. [79], based on orthogonal analysis of mass spectra 
data.  
As RNA therapeutics, synthetic siRNAs (or vectors encoding them) can be designed to target 
virtually any gene of interest (Figure 1). Synthetic siRNAs are double-stranded 21-23 
nucleotides ONs that can be introduced into cells, initiating the RNAi pathway without the 
need of Dicer [51]. However, since RNAi technologies make use of the cell’s natural 
machinery, the compatible interaction between synthetic siRNAs and RISC limits the 
position and type of chemical modifications responsible for improving nuclease resistance 
and cell uptake [80]. Consequently, in the antisense strand, phosphorothioate (PS) linkages at 
the 3ˊ-end and 2ˊ-O-methyl (2ˊ-OMe) or 2ˊ-fluoro (2ˊ-F) modifications (Table 1, § 1.4.1) in 
one or two internal nucleotides, are tolerated and improve the resistance of the siRNA to 
nucleases. The sense strand can be modified to a larger extent without reducing efficacy [77]. 
Although this approach is promising, several challenges were identified and are under 
investigation [81], including lack of stability against extracellular and intracellular 
degradation by nucleases, poor uptake [82], chemical or sequence-related toxicity [83] and 
off-target effects [75,84].  
RNAi machinery also interacts with endogenously encoded short RNA molecules known as 
microRNAs (miRNAs) [85]. miRNAs are single-stranded RNA (ssRNA) molecules with 21-
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25 nucleotides obtained by the Dicer processing of imperfect RNA hairpins [86]. Several 
genomic regions encode miRNAs, like introns or exons of protein-coding and non-coding 
regions [87]; repeats regions, like transposons [88]; and pseudogenes [89]. The miRNAs are 
incorporated into an RISC-like complex and, depending on their degree of complementarity 
to the target mRNA, promote translational repression or mRNA cleavage. Gene silencing 
mediated by miRNAs is essential for plant and animal development [90,91], and might also 
have a role in the pathogenicity of DNA viruses with large genomes that encode miRNAs 
[92].  
While post-transcriptional gene silencing induced by the siRNAs and miRNAs is based on 
RNA–RNA sequence recognition and base pairing, RNA-DNA interactions are also possible. 
Consequently, RNAi processes were found to be associated with gene regulation at the 
genomic level [78,93–101]. 
siRNAs [84] and miRNAs [87] have been used especially as cancer therapeutics, having 
currently 17 clinical trials registered for siRNAs and 155 for miRNAs (source 
https://clinicaltrials.gov/). In parallel, other human genetic, as well as infectious diseases have 
also been explored, such as Alzheimer, Parkinson, Myopathies, Familial 
Hypercholesterolemia (FH), Transthyretin (TTR)-mediated amyloidosis [102], Hepatitis C 
virus infection and Haemorrhagic fevers (especially against Ebola).  
 
1.2.2 Antisense ONs 
Antisense ONs, first described as short fragments of unmodified DNA [25], have been 
subject to several improvements with the incorporation of numerous chemical modifications 
(Table 1, § 1.4). Two antisense drugs are on the market (Vitravene™ for the treatment of 
cytomegalovirus retinitis and Kynamro™ for the treatment of Homozygous FH), and 
successful clinical trials are underway [75].  
The antisense mechanism is based on the ribonuclease H1 (RNase H1) endonuclease activity 
to specifically recognise and cleave the RNA strand of the RNA⁄DNA hybrid substrates 
[76,103] (Figure 1). Based on the structure of human RNase H:RNA⁄DNA, the protein 
interacts with eleven base pairs of the hybrid. The enzyme-substrate interactions occur at the 
minor groove of the RNA/DNA hybrid, and both backbones are moved into respective 
enzyme grooves. The active site is located in the RNA-binding groove, which interacts with 
the 2ˊ-OH groups of four consecutive ribonucleotides, two on each side of the phosphate to 
be cleaved. The two DNA-binding grooves interact with seven DNA nucleotides and, most 
likely, recognise the DNA strand by the absence of 2ˊ-OH groups and strand conformation, 
which must be compatible with the distortion induced in the phosphate-binding pocket [104]. 
The RNA cleavage occurs within or immediately adjacent to the DNA complementary region 
[26]. Recent studies by Lima et al. (2016) show that, after RNase H1 cleavage, the mRNA 
products are degraded by the cytoplasmic 5ˊ to 3ˊ exoribonuclease XRN1, a member of the 
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RNA surveillance machinery and involved in the deadenylation-independent mechanism 
associated with nonsense-mediated decay of RNAs [105].  
In a similar way to siRNAs (§ 1.2.1), not all chemical modifications can be employed in 
antisense ON design due to the specific structural requirements for RNase H1 activity [106]. 
Typically, an antisense ON is about 14-22 nucleotides long and has a phosphodiester (PO) or 
PS backbone [74]. The 2-5 nucleotides at each flank are further modified, normally with 2ˊ-
OMe, 2ˊ-O-methoxyethyl (2ˊ-MOE), locked nucleic acid (LNA) [33,34] (Figure 6, § 1.4.2) 
or unlocked nucleic acid (UNA) [107] modifications. This design, designated as ‘gapmers’, is 
characterised by a 10-nucleotide PS or PO (depending on the flanking modifications) central 
gap that allows the cleavage of the targeted mRNA by RNase H1 [26,69,75,108–111]. The 
modified flanks improve the binding between antisense ON and mRNA by increasing the 
duplex Tm, allowing better efficiency by reducing the side effects associated with the 
presence of PS residues, and protects from exonucleases increasing the stability in vivo [111].  
Unfortunately, antisense ON design is based on a “trial and error” approach due to the 
inability to predict target accessibility, which is dependent on protein binding or internal 
RNA secondary structure. However, mRNA regions containing the tetranucleotide GGGA 
motif are considered as preferred targets for this approach, as reported by Tu et al. [112]. 
Like siRNAs, these ONs present poor intracellular uptake and chemistry-dependent toxicities.  
Therapeutically, antisense ONs were tested in more than 100 clinical trials directed to 
gastrointestinal malignancies; genitourinary and gynecologic cancers; brain, lung and skin 
malignancies; and hematologic malignancies [84]. Additionally, therapies were also 
developed for Homozygous FH (Apolipoprotein B) [113,114], Duchenne Muscular 
Dystrophy (DMD), Multiple Sclerosis (MS), Myasthenia gravis, Hepatitis C, Diabetes, 
Macular degeneration, surgery related fibrosis and dermal scarring, Rheumatoid arthritis 
(RA), Crohn’s disease, Psoriasis, and Asthma (for more details, review [69,115]) 
 
1.2.3 Steric-blocking ONs 
Steric-blocking ONs comprehend distinct mechanisms to block RNA and differ from the 
previous (§ 1.2.1 and § 1.2.2) by the absence of RNA degradation (Figure 1). Depending on 
the targeted sequence regions at the pre-mRNA or mRNA, the end-products obtained will be 
different [23,44,75]. The basic requirements for the design of this type of ONs are the 
resistance to endo- and exonucleases together with specificity and affinity to the target, 
therefore any chemical modification (§ 1.4) that fulfils this requirement can be used.  
Accordingly, ONs (designated translation-suppressing ONs) can efficiently inhibit mRNA 
translation either by disruption of the ribosomes; or by binding regions of mRNA (5’ 
untranslated (5’ UTR) [116], 3’ untranslated (3’ UTR) [117] or translation initiation codon); 
or affecting elongation steps of protein translation. The control of translation is one of the 
most important mechanisms for post-transcriptional regulation of gene expression since 
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determines the final levels of the protein [118]. The initiation of translation [119] is a rate-
limiting step of the protein synthesis, controlled by translation -silencing or -enhancing cis-
acting elements located in the 5’ UTR and 3’ UTR of mRNAs [120]. Thus is not surprising 
the choice of this region as putative targets for ONs. Steric blockade of translation was 
initially demonstrated by binding of peptide nucleic acid (PNA) oligomers (Figure 6, § 1.4.3) 
to the translation initiation codon region of the Ha-Ras mRNA, with concomitant formation 
of a truncated product [121,122]. One amazing example of this type of mechanism relates to 
studies of phosphorodiamidate morpholino oligomer (PMO)-based ONs to decrease Ebola 
virus in infected monkeys by inhibition of viral mRNA translation (in clinical trials) [123]. 
On the other side, external guide sequence (EGS), consist of short RNA ONs that bind to 
mRNA and form a structure recognised by the ribonuclease P (RNase P), which cleaves the 
mRNA preventing the translation of the protein [75]. This approach is being developed 
especially for antibacterial and antiviral purposes [124], since RNAi mechanisms (§ 1.2.1) 
cannot be used in prokaryotes. As antibacterial agents, EGS ONs were developed as 11-mer 
PMOs ON (for expression reduction of the acyl carrier protein in Escherichia coli) [125] or 
as cell penetrating peptides conjugated (CPP) PMOs (PPMOs) (§ 1.5.2) (several genes in E. 
coli and Bacillus subtilis, with infection reduction) [124]. As antiviral agents, EGS ON was 
reported to decrease the human cytomegalovirus (HCMV) infection in cells by binding to the 
mRNA that encodes the protease essential for viral capsid formation and replication [126].  
Similarly, ONs can also bind to mRNA sequences involved in secondary structure formation, 
compromising the proper folding and interfering with mRNA stability or function [23,44]. 
These structures function as recognition motifs for some proteins, nucleic acids, and 
ribonucleoproteins that participate in the intermediary RNA metabolism or activities of RNA 
species. Thus, ONs can prevent 5’-cap formation, dictate the site for polyadenylation and 
folding of target mRNA [115]. One example is the binding of PS ONs to the trans-activation 
response (TAR) elements (stem-loop present in all HIV RNA species), disrupting the loop 
formation and inhibiting the TAR-mediated production of a reporter gene [127,128].  
Additionally, ONs can also bind to toxic RNAs avoiding the accumulation of protein factors 
at expanded triplet repeats [75]. One specific example is the case of myotonic dystrophy 
disease (DM1), characterised by an expansion of the CTG repeats located in the 3′ UTR of 
the gene encoding the dystrophia myotonica protein kinase (DMPK). This expansion 
generates a defective, expanded CUG repeat-containing mRNA, which cannot be correctly 
spliced and accumulates in the nucleus [129]. It happens that this expanded CUG repeat binds 
and sequester the splicing factor, muscleblind-like protein 1, which is then unavailable for the 
splicing of pre-mRNA from several other genes, including the muscle-specific chloride 
channel protein 1 (CLCN1). The absence of this channel results in the hyperexcitability of the 
muscle, which causes the myotonia [130]. The interaction between the expanded repeats and 
the splicing factor can be reversed in vivo using a 25-mer (CAG) PMO ON as shown by 
Wheeler et al.[131]. Additional two therapeutic approaches, involving other steric blocking 
mechanisms, were also developed in DM1. Mulders et al. reported, in vitro and in vivo, 
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expression silencing of the mutant DMPK RNA and reduction of ribonuclear aggregates 
using a 21-mer (CAG) 2’-OMe/PS fully modified ON (Figure 6, § 1.4.1) in a selective and 
(CUG)n-length-dependent way [132]. Nakamori et al. reported, also in vitro and in vivo, with 
two 18-mer fully PS/LNA ONs (Figure 6, § 1.4.2), the reduction of CUG expanded 
transcripts as a consequence of repeat stabilisation at the genome level due to the reduction of 
R-loops (Figure 5, § 1.3.3) formed at the repeat sequence [133].   
     
1.2.3.1 Splice modulating therapies 
Splice modulation is also a steric blocking ON mechanism and is mediated by splice-
switching or splice correction ONs (SSOs and SCOs, respectively) (Figure 1).  
Splicing of pre-mRNA is a complex and tightly regulated process, consisting in the concerted 
removal of the pre-mRNA introns and ligation of exons. This process is catalysed by the 
spliceosome, a ribonucleoprotein complex [134] highly conserved in eukaryotes, and occurs 
in almost all of our genes. Splicing of each intron involves two sequential transesterification 
reactions. The first reaction releases the 5ˊ exon from the downstream intronic sequence and 
the formation of a lariat structure. The second reaction releases the lariat from the 
downstream, 3ˊ exon and ligates together the 5ˊ and 3ˊ exons [135]. In principle, a 5ˊ splice 
site can splice to any 3ˊ splice site, which can result in alternative splicing events [136,137].  
Alternative splicing is the mean by which two or more different mRNAs can be produced 
from a single gene by the alternative inclusion/exclusion of particular sequences of the pre-
mRNA. Thus, a single gene can produce protein isoforms with different and even opposite 
functions [138]. Alternative splicing has been estimated to occur in 40-60% of human genes 
[139,140]. This high abundance of an occurrence likely explains a certain amount of the 
functional differences between cell types and suggests that cells can tolerate different 
isoforms of mRNA and proteins. [141]. 
Canonical and alternative pre-mRNA splicing requires precision and accuracy to maintain the 
proper open reading frame, in a way to obtain effective protein production. This high fidelity 
is dictated by genomic sequences, including 5ˊ and 3ˊ splice sites (5ˊss and 3ˊss); intron 
branch site; and splice site enhancers and silencers found within both exons and introns. The 
auxiliary cis-elements, known as exonic or intronic splicing enhancers (ESEs and ISEs) and 
exonic or intronic splicing silencers (ESSs and ISSs) help in the exon recognition  [134,135].  
Four classes of pre-mRNA splicing defects are described as causing disease. The cis-acting 
mutations that disrupt the use of constitutive splice sites; cis-acting mutations that disrupt the 
use of alternative splice sites; trans-acting mutations that disrupt the basal splicing machinery; 
and trans-acting mutations that disrupt splicing regulation [138]. The majority of the splice-
associated diseases occur through cis-acting mutations. 
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In a way to modulate pre-mRNA splicing, SSOs or SCOs must block the RNA sequences 
essential for splicing and prevent the interaction of splicing factors, such as RNA-binding 
proteins, small nuclear RNAs and other components of the spliceosome, with the pre-mRNA. 
The mechanisms proposed for the action of ON have been widely revised [75,138,141–143] 
and can be found schematized in Figure 2.  
 
 
 
Figure 2: Splice modulation therapies. A) Large-scale deletions can result in out-of-frame 
mRNA. ONs can mediate the exclusion of the exon and reformation of an in-frame transcript. 
B) ONs can also be used to modulate the incorporation of exons, which are predominantly 
excluded from mRNA transcripts forcing the use of alternative 5’-splice site. C) Cryptic 
splice sites are weak recognition sites used only when a mutation disrupts the authentic splice 
site, by creating a 5ˊss which activates a cryptic 3ˊss. They can be found within an intron or 
exon, resulting in the inclusion of intron parts or partial deletions of exons from mRNA, 
respectively. ON targeting the mutated 5ˊss, blocks recognition by the splicing machinery and 
generates transcripts without the aberrant intron element D) Pseudoexons, or false exons, are 
intronic sequences with strong but unused 5ˊ and 3ˊss at either end. These sequences are 
infrequently found in the mature mRNA sequence. Exclusion of pseudoexons from mRNA 
can be attributed, in part, to silencer elements and the secondary structure of the pre-mRNA. 
Pathological pseudoexons arise from mutations that create a splice donor or acceptor site 
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either de novo or within a weak and normally unused splice site. Other mutations resulting in 
the incorporation of pseudoexons include the generation of novel branch point sites and 
creating or deleting splice regulatory elements that bind trans-splicing enhancers or silencers. 
( ----- ) stands for abnormal splicing. 
 
SSOs or SCOs are typically 15-30 nucleotides long and have to be completely modified with 
chemical modifications (combined or not) that improve binding affinity and stability, 
including e.g. 2ˊ-OMe PS, 2ˊ-MOE PS, LNA PS, and  PMO [69,75,141] (§ 1.4). Shown to 
work in animal models include, PNA oligomers, alternating LNA and deoxynucleotide ONs, 
fully modified 2′-MOE ONs, fully modified 2′-OMe ONs and PMO-based oligomers [141].  
The efficiency of ONs therapeutics as splice modulators (SSOs and SCOs) has been reported 
for several diseases including cancer [84], metabolic [144], neurodegenerative [115], 
inflammatory, immunodeficiency and viral (Ebola). The therapeutic application of SSOs is 
most advanced in DMD but, the same compounds are also being studied as potential 
treatments for spinal muscular atrophy (SMA) and β-thalassaemia, as well as RA [141]. 
 
1.3 OLIGONUCLEOTIDE THERAPIES – GENOMIC APPROACHES 
 
ONs have also been developed to target genomic DNA and thus regulate the gene expression 
at the transcriptional level (Figure 1). Like RNA therapeutics (§ 1.2), also the anti-gene 
approach is based on sequence-specific targeting using DNA- or RNA-based ONs. 
Four mechanisms have been reported for gene expression regulation by ONs at the genome 
level. Through binding of triplex-forming ONs (TFOs) to the major groove of dsDNA (§ 
1.3.1); invasion of DNA duplex (§ 1.3.2); chromatin remodelling and epigenetic gene 
silencing by miRNAs [78,145] (§ 1.2.1); or destabilisation of non-B DNA structures and R-
loops (Figure 5, § 1.3.3).   
 
1.3.1 Triplex-forming oligonucleotides (TFOs) 
The possibility for formation of DNA triplex structures was suggested by Pauling and Corey 
[146] and demonstrated experimentally by Fesenfeld et al.[147] by showing that poly(U) and 
poly(A) strands in a 2:1 ratio were capable of forming a stable complex in the presence of 
Mg
2+
. DNA triplex structures are formed at polypurine-rich regions of dsDNA, through 
binding of triplex forming ONs (TFOs) to the major groove of the duplex forming Hoogsteen 
hydrogen bonds [148] or reverse Hoogsteen hydrogen bonds, in parallel or antiparallel 
orientation, respectively [149].  
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Parallel triplexes are formed by TFOs with TC or GT motifs, originating d(T:A-T), d(C:G-G) 
and d(C:G-C+) triads formed through Hoogsteen hydrogen bonds. Antiparallel triplexes are 
typically formed by purine (GA) or mixed (GT) TFOs forming d(T:A-A), d(C:G-G) and 
d(T:A-T) triplets through reverse Hoogsteen hydrogen bonds [43,150] (Figure 3).  
 
 
Figure 3: DNA triplex structures with parallel and antiparallel orientation. 
 
Consequently, the success of TFOs as anti-gene therapeutics is dependent on the density and 
genomic localisation of specific polypurine:polypyrimidine-rich regions, designated as triplex 
target sequences (TTS). Bioinformatics and wide analysis studies have shown that TTS are 
over-represented in the human genome at regulatory regions, especially in promoter zones 
[151]. Structurally, TTS are significantly more curved and rigid than normal DNA, 
suggesting that they act as spacing fragments, helping in the correct positioning of 
transcription factors [152]. 97.8% of known human genes have at least one potential high-
affinity TTS in the promoter and/or transcribed gene regions and 86.5% of these genes have 
at least one TTS that is unique for that gene [153]. 
Three TFO applications have been reported: interference with DNA repair (site-directed 
mutagenesis, site-directed recombination) in vitro and in vivo [154–157]; location of DNA-
mutagenic compounds with direct site-specific DNA damage [46,158,159]; and modulation 
of gene transcription [160,161].  
TFOs can modulate gene transcription (e.g. in c-myc [43], ets2 [162], ICAM-1 [163]), 
inducing down-regulation of genes by preventing protein binding to DNA [164,165]; and by 
inhibiting DNA replication (e.g. in simian SV40 [166] and HIV-1 [167] virus) [168].  
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While promising, TFO antigene strategies show low intracellular efficacy, probably due to 
cellular environment conditions. Like any RNA therapeutic ON, TFO needs to be taken up by 
cells (§ 1.5) and be resistant to nucleases. Moreover, they need to be able to form triplexes at 
physiologic pH, overcome charge repulsion between TFO and dsDNA, endure the chromatin 
environment and be stable enough to compete with endogenous proteins [169]. The use of 
PNA (§ 1.4.3) and LNA (§ 1.4.2) chemical modifications seem to overcome the nuclease 
resistance, the efficient binding and triplex formation challenges, at least in vitro.  
 
1.3.2 Invasion of DNA duplex 
Another mechanism in antigene strategies is the invasion of DNA duplex by ONs and 
includes three different approaches in vitro (Figure 4).  
1) Invasion of the DNA duplex and binding of a linear ON to the sense-strand by 
Watson-Crick (WC) bonds, leaving the antisense-strand displaced;  
2) Invasion of the DNA duplex and binding of the ON simultaneously to both sense- and 
antisense strands by WC bonds; 
3) The TFO-arm of the “bis” ON binds via Hoogsteen hydrogen bonds to the sense-
strand, while the WC-arm strand invades the duplex and hybridises with the same 
strand. The antisense strand is displaced. 
 
 
Figure 4: Schematic representation of the three invasion approaches of DNA duplex. 
  
Invasion of DNA duplex (Figure 4 (1)) associated with transcription inhibition was reported 
for the first time for linear PNA oligomers targeting the tandem CAG repeats and leading to 
transcription inhibition of the androgen receptor and TATA-binding protein genes. The 
analysis of the corresponding transcripts confirmed the progression arrest of the RNA 
polymerase complex in both directions outside the location of PNA/DNAhybridization [170]. 
Down-regulation of the c-myc gene was also obtained when a PNA ON conjugated to a 
nuclear localisation signal (NLS) peptide, was targeted to a unique sequence located in the c-
myc second exon [171]. Inhibition of the human progesterone and androgen receptors 
expression was also achieved and reported by Corey and co-authors, using linear PNA [172] 
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(§ 1.4.3), LNA [173] (§ 1.4.2) and peptide-conjugated PNA [174] oligomers targeting the 
promoter regions.  
The second approach for DNA duplex invasion (Figure 4 (2)) was developed in our lab using 
LNA ONs (§ 1.4.2) targeting both sense- and antisense-strand. In this construct, a 14-mer arm 
binds to the sense strand, while a 16-mer arm binds the antisense strand. The two arms can 
hybridise (5’-end with 3’-end) through a bridge of seven base pairs, acquiring a Z-like 
structure (Zorro-LNA) [175]. Zorro-LNA demonstrated good strand invasion in plasmids, 
and the reporter gene transcription was blocked in transfected cells. The construct was further 
optimised to be smaller and easier to design, resulting in a 3’-5’-5’-3’ single-stranded  Zorro-
LNA (ssZorro) by using both 3’- and 5’-phosphoramidites [176]. This new construct shows a 
higher rate of double-strand invasion (DSI) as compared to Zorro-LNA.  
In 2011, Ling et al. reported the use of Zorro-LNA targeting a single CTCF binding site at the 
neurofibromatosis gene locus and consequent alteration of long-range DNA interactions in 
human fibroblast cells [177]. Recently, Bohländer et al., using synthetic ON, reported that 
this type of invasion approach also works when two pyrrolidinyl PNA oligomers are used 
[178]. 
The third approach is based on “bis” ONs (Figure 4 (3)), composed by a TFO-arm and a 
WC-arm connected by a linker. In this concept, the TFO-arm recognises the polypurine 
region of the target site, while the WC-arm is responsible for the stand invasion of the DNA 
duplex and hybridization to the same strand. This mechanism was first reported for bisPNA 
oligomer in a plasmid context [179,180] and recently in our lab using bisLNA ON [181,182]. 
Interestingly, McNeer et al. (2015) described, in vivo, the correction of the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene F508del mutation, using bisPNA 
oligomer and a donor DNA, delivered in biodegradable polymer nanoparticles [183].       
 
1.3.3 (De)stabilisation of non-B DNA structures and R-loops 
Non-B DNA structures refer to all DNA conformations, other than the orthodox right-handed 
Watson-Crick structure, including distorted bond angles or unpaired nucleotides [184,185]. 
Non-B DNA structures include triplexes, cruciforms, G-quartets (G-quadruplex, G-tetraplex 
or G4-DNA), and slipped structures (like hairpins), among others [184] (Figure 5). Their 
formation is dependent on the DNA sequence, the orientation of the DNA strands and length. 
They can be found in promoters, 5’ UTRs, exons, introns and 3’ UTRs [186]. Intramolecular 
triplex structure, so-called H-DNA, forms at mirror repeat sequences through dissociation of 
half of the repeat double helix and “folding back” of one of the single strand produced. This 
rearrangement leads to the formation of a triple helix, stabilised by Hoogsteen or reverse 
Hoogsteen hydrogen bonds, and a single strand region (Figure 8, § 1.7). Cruciforms are 
formed in inverted repeats (i.e. palindromic sequences) of more than six nucleotides long. G-
quadruplexes are non-helical structures formed by guanine tetrads interacting by Hoogsteen 
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bonds, stacked and stabilised by monovalent cations. Slipped DNA forms in DNA repeats 
with no spacer and creates a hairpin in both DNA [149,187].  
 
 
 
Figure 5: Non-B DNA structures and R-loops. A) The formation of secondary structures or 
the presence of the sequence motif per se can lead to double-strand breaks (G-quartets, 
triplexes, cruciforms and hairpins); induction (G-quartets and GAA/TTC tracts) or inhibition 
of transcription (G-quartets and triplexes); initiation (triplexes) or stalling of replication (G-
quartets, triplexes, cruciforms and hairpins); and sequestration of cellular proteins (G-
quartets, triplexes and r(CUG) hairpins). B) R-loop could be formed due to the persistent 
interaction of nascent pre-mRNA and the repetitive DNA template during transcription, 
leading to repeat expansion and chromosomal fragility. (Adapted with permission, Biochimie 
95(2), 117-123, copyright 2013) [188] 
 
Several studies in vitro and in vivo, show that non-B DNA structures can interfere with the 
formation of the nucleosome formation, binding and elongation of RNA polymerase II, or 
interaction of specific factors with their target DNA sequences, hence promoting or inhibiting 
transcription [187]. Additionally, they can also interfere with DNA replication and trigger 
genomic instability [188]. Thus, these structures contribute to the generation of 
polymorphisms, to genome evolution and development of a variety of diseases 
[184,185,188].  
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At least two classes of human genomic disorders are strongly related to non-B DNA 
structures. Approximately 20 hereditary neurological diseases can be associated with simple 
sequence amplifications, while ~50 hereditary diseases are caused by, for example, genomic 
rearrangements and gross deletions. Less well studied, but linked to polymorphisms of simple 
repeat sequences, are some psychiatric diseases (such as schizophrenia, drug and alcohol 
abuse, attention-deficit or hyperactivity disorder, and anorexia-bulimia) (reviewed in [186]).  
Another nucleic acid structure found in the genome is the R-loop. It is composed of a DNA–
RNA hybrid and a displaced single-stranded DNA [189] and can, putatively, be formed due 
to the persistent interaction of nascent pre-mRNA and the repetitive DNA template during 
transcription. The precise mechanism by which R-loops form in vivo is still unclear, although 
three models have been proposed [190]. R-loops are more abundant than any other non-B 
DNA structures in mammalian genomes. They possess crucial roles in transcription and 
chromatin structure, but can also contribute to genome stability. In cells, several factors and 
processes limit or prevent R-loop formation and accumulation. They can be removed by 
either ribonucleases or helicases or proteins involved in the DNA damage response pathways. 
Misfunction of these factors causes R-loop accumulation, which leads to replication stress, 
genome instability, chromatin alterations or gene silencing, outcomes that are frequently 
associated with cancer and some genetic diseases (reviewed in [189,190]). 
Genomic therapies, through destabilisation/stabilisation of non-B DNA structures and R-
loops by ONs, are only at an early stage. They are similar to the RNA therapeutics (§ 1.2) and 
antigene strategies (§ 1.3), being also based on simple nucleic acids complementarity rules. 
Although, is apparent that the success and efficiency of these approaches would rely on the 
use of chemically modified analogues or nucleic acid mimics, especially strand invasion ONs 
(PNA and LNA) (§ 1.4.3, § 1.4.2). Moreover, recent studies on formation mechanisms and 
biological functions of non-B DNA structures has contributed to improved target design and 
the evaluation of drawbacks.     
ONs able to invade double strand DNA have been explored to stabilise or disrupt non-B 
DNA structures. For example, several studies proposing and assessing the interactions, 
mechanisms and conditions between G-quadruplexes and PNA or PNA derivatives oligomers 
(§ 1.4.3) have been published (reviewed in [191]). Targeting of R-loops has also been 
reported by Nakamori et al., showing that the reduction of CUG expanded transcripts, in vitro 
and in vivo, is achieved by repeat stabilisation at the genome level, due to reduction of R-
loops using two 18-mer fully PS/LNA ONs [133] (§ 1.4.2). 
ONs interaction with triplex DNA and R-loops is further described in section 1.7. 
 
1.4 NUCLEIC ACID ANALOGUES 
As highlighted in the previous sections, it is evident that the major driving force of the ON 
therapies is the constant development and improvement of nucleic acid analogues. 
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Since the synthesis of the first nucleic acid analogue, 2ˊ-fluoro, several chemical 
modifications of the natural ONs have been studied. Included are modifications in the 
phosphodiester (PO) backbone, the sugar moiety or heterocyclic nucleobase [69,108,111]. 
The objective in designing new analogues is to improve specific properties such as nuclease 
resistance, the process of synthesis, affinity and selectivity, and in some cases the ability to 
cross biological membranes [69,108,110,192].   
Nuclease degradation can be avoided by modifying either the PO backbone, heterocyclic 
nucleobases or sugar moiety [69,108]. Additionally, to increase target affinity and biological 
potency, modifications in the sugar moiety or heterocyclic nucleobases are used.  The 
combination of different chemistries is also exploited for solving problems such as low 
sequence specificity, self-aggregation, and potential toxicity [109,110]. Cellular uptake of 
modified ONs can be further increased by conjugation to a wide variety of ligands: 
cholesterol derivatives, poly(L-lysine) tail, and shorter positively charged cell-penetrating 
peptides (CPPs), among others (reviewed in [108,192] (§ 1.5). 
Different ON therapy approaches require specific or combination of chemical modifications 
(for examples see § 1.2 and 1.3). Only the most appropriate chemical modifications to work 
included in this thesis will be presented. The chemical structures of these analogues are 
shown in Figure 6, and they are further discussed in the next sub-sections. 
 
 
 
Figure. 6. ON chemical modifications. Phosphorothioate (PS) backbone [8], 2ˊ-O-methyl 
(2ˊ-OMe) substituent [30], Locked nucleic acid (LNA) modification [33,34], Peptide nucleic 
acid (PNA) [32]. 
 
Notwithstanding, additional chemical modifications are available, and constantly new ones 
arise. 
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1.4.1 2ˊ-O-methyl phosphorothioate (2ˊ-OMe/PS) 
2ˊ-O-methyl phosphorothioate (2ˊ-OMe PS) ONs are an example of the so-called second-
generation modifications. They combine structural modifications of the backbone linkage 
(PS) [8,111] with a methyl substituent in the 2ˊ- position of the sugar moiety (2ˊ-OMe) [30] 
(Figure 6). The PS backbone confers sufficient resistance to nuclease degradation, leading to 
higher bioavailability, carries a negative charge which is advantageous for cell delivery, and 
displays attractive pharmacokinetic properties and cellular uptake due to increased binding to 
plasma proteins and other receptor sites as compared to PO [111]. The 2ˊ-OMe modification 
increases even further the resistance of the ON preventing endonuclease and exonuclease 
cleavage, increases binding affinity and modulates ON binding to proteins [108,109,193]. 
Fully 2ˊ-OMe PS modified ONs prevent the RNase H1 activation and the nuclease 
degradation of the corresponding mRNA strand; which make them unique molecules for 
splicing modulation (§ 1.2.3.1). Furthermore, 2ˊ-OMe PS have been extensively used as 
steric-blocking ONs (§ 1.2.3).  
2ˊ-OMe PS ONs have been successfully used in animal models targeting apolipoprotein B-
100 mRNA in Homozygous FH [113],  DM1 mRNA in DM1 [194], and huntingtin mRNA in 
Huntington's disease [195], and in human clinical trials against apolipoprotein C-III mRNA 
in severe hypertriglyceridemia and familial chylomicronemia [196], and against transthyretin 
mRNA in transthyretin-associated polyneuropathy [197]. 
 
1.4.2 Locked Nucleic Acid (LNA) 
Locked nucleic acid (LNA) is an RNA analogue in which the ribose is conformationally 
locked by the introduction of a 2ˊ-oxygen and 4ˊ-carbon-methylene linkage [33,34] (Figure 
6). The presence of this bridge promotes a conformational restriction in LNA 
oligonucleotides, favouring duplex formation. They also exhibit high thermal stabilities when 
hybridised with their RNA target molecules [108,198].   Due to the sugar conformation, LNA 
is resistant to 3′ exonucleases, lacks (in no-gapmer ONs) RNase H1 (§ 1.2.2) or RISC (§ 
1.2.1) activity. The presence of LNA at the 3′ end of siRNA sense, or passenger, strands 
increases lifetime in blood, and thus potency of this ONs, but also enhances off-target effects 
[69,108].  
Recently, LNA has been used to modify triplex forming oligonucleotides (TFOs) (§ 1.3.1) to 
increase triplex thermostability and affinity at near-physiological pH [181,182]. Like PNA (§ 
1.4.3), LNA is also able to invade double strand DNA and binds strongly through Watson-
Crick hydrogen bonds to DNA complementary sequences [181] (§ 1.3.2). 
LNA-modified oligonucleotides have been extensively exploiting in different therapeutical 
areas, such as antisense mechanisms to induce RNA degradation by RNase H1 (§ 1.2.1), 
siRNA-mediated degradation (§ 1.2.2), altered pre-mRNA splicing (§ 1.2.3.1), blocking of 
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microRNA, and as antigene reagents to block transcription of a specific gene (§ 1.3) 
[198,199] or as decoy ON for sequestering of transcription factors [200]. 
 
1.4.3 Peptide Nucleic Acid (PNA) 
Peptide nucleic acid (PNA) is a DNA mimic with an uncharged, flexible, pseudopeptide 
backbone composed of repeated N-(2-amino-ethyl)glycine units to which the nucleobases are 
linked through methylene carbonyl linkers [32,69] (Figure 6). PNA exhibit improved 
hybridization characteristics of DNA and RNA, forming very stable duplexes and triplexes 
with complementary ssDNA, dsDNA or RNA in a sequence-specific way [23,32,108]. This 
high-affinity can be explained by the lack of electrostatic repulsion due to the absence of 
negative charges on the PNA oligomers. 
PNA is not a substrate for RNaseH and exerts its antisense effect by forming a sequence-
specific duplex with mRNA, causing steric hindrance of the translational machinery, and 
leading to protein knockdown [69] (§ 1.2.3). Additionally, cell-free in vitro studies confirmed 
the potential of PNA as a sequence-specific inhibitor of transcription and translation due to 
the formation of the triplex complexes (§ 1.3.1), steric blocking of transcription factors, 
duplex formation at the intron-exon junction of RNAs or inhibition of viral reverse 
transcription. However, the application of PNA oligomers as therapeutic drugs was 
compromised by their poor intrinsic uptake by living cells [108,110]. Since PNAs are 
uncharged molecules, the majority of non-viral delivery vectors (§ 1.5), cannot be used. 
Recently nanoparticle-based strategies for efficient delivery of conventional and chemically-
modified PNAs have been developed (reviewed in [201]) and proved to be effective [183].   
Homopyrimidine PNA (bisPNA) oligomer, binding to dsDNA, results in a triplex invasion 
complex [202] (§ 1.3.2). The thermal stability of triplex invasion complexes is very high, but 
the formation is slow at physiological concentrations of salt [203]. PNAs have also been 
combined with intercalating moieties and nucleobases analogues (thio-pseudoisocytosine and 
pseudoisocytosine), to improve PNA oligomer efficiency of RNA recognition [204]. 
 
1.5 DELIVERY VECTORS 
 
Despite the advances regarding ONs optimisation, the transfer of ON therapies from the lab 
to the clinics has been very slow. 
The problem? ONs have poor efficacy in vivo. It does not mean that they “don’t work”, but 
simply because it is very challenging to obtain efficient delivery of such large, polar 
molecules to their target sites of action within tissues. Thus, the major drawback in ON 
therapies is still the availability of safe and efficient delivery vectors, especially in vivo [205].  
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While being the most explored and used in the gene therapy field, viral vectors are still 
limited by the risk of carcinogenesis, immunogenicity, broad tropism, limited DNA 
packaging and difficulty of vector production. On the other side, non-viral vectors are safer, 
can deliver higher amounts of genetic material and are easier to synthesised, but show poor 
efficiency in transporting the genetic material through the several cellular barriers [192,205]. 
Notwithstanding, recently developments in the field of material sciences (new polymers and 
lipids), nanotechnology (nanosized materials) and nucleic acid chemistry (an increase of 
potency and stability, and reduced immunogenicity), can be an option to overcome those 
problems. 
Regarding the delivery in vivo, several factors have to be considered to achieve efficiency. 
The system must protect the therapeutic agent from degradation by endonucleases in 
physiological fluids and the extracellular space, avoid aggregation in capillaries or interaction 
with blood components, and allow selective accumulation at the tissue of interest, cellular 
internalisation, endosomal escape, provide transport into the nucleus (if required), and finally 
release of cargo [206]. 
ONs therapeutics can be delivered by physical and synthetic methods [207]. Physical 
methods include e.g. the electroporation as an option to transfect primary monocytes in vitro, 
and the injection with naked ONs which is a common choice in clinical trials. Regarding the 
synthetic delivery vectors, several perspectives have been explored for in vitro and in vivo  
delivery [82,205], like lipoplexes and lipid nanoparticles (e.g. cationic lipoplexes) [208,209] 
(§ 1.5.1); lipopolyplexes and polyplexes [210,211]; cationic polymers (linear and branched 
polymers, dendrimers [212] and polysaccharides); polymersomes, cell-penetrating peptides 
(CPPs) [213,214] (§1.5.2); and inorganic nanoparticles [215].  
As for nucleic acid analogues section, also here only the delivery vectors related to this thesis 
will be described in more detail. 
 
1.5.1 Cationic Liposomes 
Lipid nanoparticles (LNs) are one of the best optimised and characterised ON therapeutics 
delivery systems in vitro and in vivo [216]. LNs are subdivided depending on the formulation 
method, which is based on the physicochemical properties of their lipids. Accordingly, they 
include cationic lipoplexes, neutral liposome, lipid and step-wise bulk mixing (reviewed in 
[216]). 
Cationic lipoplexes are complexes of plasmid DNA or ONs with cationic liposomes and are 
the LN most used for nucleic acid delivery [211]. 
Cationic liposomes are composed of cationic lipids with a neutral helper lipid. Cationic lipids 
consist of a DNA-interacting head group with a net positive charge at physiological 
conditions or at lower pH; a hydrophobic lipid anchor group such as cholesterol or fatty acid 
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chains of various lengths and unsaturation states; and a linker group that binds the polar 
group to the lipidic moiety. The head group interacts with the negatively charged phosphate 
backbone of the ONs, thus forming a compact structure. Together with the additional neutral 
helper lipids, the transfection complex builds a monolayer, liposomal structure with a positive 
surface charge in aqueous solutions. The interaction with the cell membrane is mediated by 
this positive charge of the liposomes [209,217]. Following the cellular uptake by endocytosis, 
the lipidic moiety destabilises the endosomal membrane, resulting in a flip-flop 
reorganisation of the phospholipids. The endosomal phospholipids diffuse into the liposome 
and interact with the cationic lipids, causing the DNA dissociation and diffusion to the 
cytosol [215]. 
Lipofection is a popular transfection method and defines the process by which cationic 
liposomes interact with the ON spontaneously, fuse with the tissue culture cells, and facilitate 
the delivery of the ON into the cell. Lipofection is appropriated for cell lines and many 
primary neonatal cells. The technique is simple, highly reproducible, and more efficient when 
compared with (other) chemical methods leading to a 5- to 100-fold increased transfection 
rate depending on the cationic liposome. [207,208]. 
Although, cationic liposomes are limited to deliver only negative charged ONs (e.g. 2ˊ-OMe 
PS, LNA) and plasmids. Also, they are big, show cytotoxicity at high concentrations, and 
demonstrate low efficacy in vivo delivery, owing to poor stability and rapid clearance, as well 
as the generation of inflammatory or anti-inflammatory responses [205,217]. Nonetheless, 
various liposomal formulations continue to be developed clinically. 
Lipofectamine (or Lipofectamine 2000) is a 3:1 (wt/wt) formulation of the polycationic lipid 
DOSPA and the neutral lipid DOPE. It is commercially available and is the cationic liposome 
most used in cell assays for delivery of ON therapeutics and plasmids [209]. 
 
1.5.2 Cell-penetrating peptides (CPPs) 
Cell-penetrating peptides (CPPs) are one of the most relevant tools for the intracellular 
delivery of a wide variety of cargoes such as proteins, nanoparticles, small molecules and 
nucleic acids (including ONs).  
CPPs are usually short amphipathic or cationic (although anionic CPPs were reported) amino 
acid sequences with the capacity to translocate across cellular membranes [218]. They can be 
classified, based on their amino acid composition, as primary amphipathic, secondary 
amphipathic or non-amphipathic (reviewed in [214]). Despite their diversity, CPPs share 
common features among them. They contain natural or non-natural amino acids; are usually 
between 5-40 amino acids in length; carry a net- positive charge; and can transport one or 
more types of covalently or non-covalently conjugated bioactive cargoes over the cell 
membrane [219].  
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The major drawback of CPPs is the lack of knowledge about what exactly drives the 
translocation of the cargo into the cell and the mechanisms through which this occurs [218]. 
While non-endocytic internalisation routes have been described [220] the vast majority of the 
studies, to date, suggest that endocytosis is the principal mechanism for cellular uptake of 
CPPs. In this process, all classical endocytosis subtypes, including micropinocytosis; clathrin-
mediated; and caveolin/lipid raft-dependent endocytosis have been shown to be involved 
[218]. CPPs present several advantages like a rapid delivery of cargoes into cells, are stable in 
physiological buffers and usually show low toxicity [218]. They can bypass biological 
membranes such as the intestinal membrane and the blood-brain barrier (BBB) [221,222] and 
don’t are immunogenic [223].  
Two clear strategies for delivery of ONs into cells are reported. The first strategy involves the 
synthesis of CPP-ONs covalent conjugates and yields distinct chemical entities but is often 
limited to short and uncharged ONs. Additionally, despite being less toxic, the transfection 
efficiencies are lower than those achieved for lipid-based vectors such as (Lipofectamine™ 
2000). Notwithstanding, the most advanced studies in the CPP field involved the use of these 
conjugates for RNA splicing regulation. The second approach is based on the formation of 
CPP/ON non-covalent complexes or nanoparticles by electrostatic interactions. While these 
complexes are easy to form, their size distribution might be wide; their exact chemical 
composition is not well-defined and is not compatible with all CPPs. However, it enables the 
delivery of negatively charged ONs, such as modified and unmodified RNA and DNA, as 
well as RNAi effectors and plasmids. [214,219]. This strategy is less laborious and requires 
lower concentrations of ONs to achieve the same biological effect as with CPP-ON 
conjugates. One limitation to this strategy exists. Since the delivery is endocytosis-driven, 
much of the delivered cargo becomes entrapped in the endosomes. 
In a way to enhance endosomal escape, several modifications were introduced such as the N-
terminal stearic acid modification (e.g. the stearic acid-modified CPPs, stearyl-TP10 ) [213]. 
PepFect 14 (PF14) is a modified version of the stearyl-TP10, by replacement of lysines and 
isoleucines with ornithines and leucines. It demonstrates unusual splice-correction activity in 
vitro and can be converted into a stable solid formulation retaining the activity [224]. 
 
1.6 HYPERCHOLESTEROLEMIA – PCSK9 
 
Hypercholesterolemia is a medical condition characterised by high levels of low-density 
lipoprotein cholesterol (LDL-C) in plasma [225,226]. The actual therapy is based on the use 
of statins, a class of cholesterol-lowering drugs [227]. While considered efficient and safe, 
they present some limitations at higher doses and do not sufficiently reduce LDL-C in high-
risk or very high-risk subjects, requiring add-on therapies [226]. In a way to identify 
additional pharmaceutical targets, several genes and correspondent coded proteins involved in 
the cholesterol metabolism regulation were studied. One of the most promising is the 
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proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 was discovered in 2003 [228] 
and identified as the third locus associated with autosomal dominant hypercholesterolemia 
[229].  
In 2005, a study from K. Maxwell et al. demonstrate that overexpression of PCSK9 mediated 
by an adenoviral vector accelerates the degradation of the low-density lipoprotein receptor 
(LDLR) in hepatic cells [230]. Parallel, other studies have shown the relation between gain 
[231–233] and loss [234] of function mutations in PCSK9 with the corresponding increase 
and decrease in LDL-C levels in the blood, respectively.  
LDLR is the cell surface receptor that mediates the cellular internalisation of LDL-C by 
clathrin-mediated endocytosis for further degradation in the lysosomes, thus crucial in the 
cholesterol metabolism regulation. Normally, after reaching the endosome, the LDLR 
receptors detach from the LDL-C particles, escape from the endosome and are recycled to the 
membrane cell. PCSK9 is a natural post-transcriptional inhibitor of LDLR (Figure 7).  
 
 
Figure 7: PCSK9 post-transcriptional regulation of LDLR. A) Regulation of hepatic LDL 
receptor expression by proprotein convertase subtilisin/kexin type 9. B) Mechanism of low-
density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 
inhibition (Reprinted with permission from Oxford University Press: European Heart Journal 
36(36), 2415-2424, copyright 2015) [250]. 
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Briefly, PCSK9 binds to LDLR on the surface of cells and the PCSK9-LDLR complex is 
internalised. In the acidic environment of the endosome, the affinity of PCSK9 for the LDLR 
increases and LDLR is “forced” to follow the degradation pathway until the lysosomes, 
where it is degraded [235,236].   
PCSK9 is mainly expressed in the liver, small intestine, kidney and central nervous system 
[237] and mediates the degradation of LDLR not only in hepatocytes, but also in fibroblasts 
and macrophages, but not in kidney or adrenals [238]. In 2008, Schmidt et al. described the 
existence of a PCSK9 splice isoform (PCSK9sv), which is expressed in multiple tissues, but 
contrary to full-length PCSK9 (PCSK9fl), does not show activity in controlling cellular levels 
of LDLR protein [239]. PCSK9sv differs from PCSK9fl by an in-frame deletion of exon 8, 
preventing autocatalytic cleavage of the pro-domain and secretion of the protein. 
Several therapies have been developed in the last years, with variable outcomes, aiming to 
decrease the expression or the activity of the PCSK9 protein [240,241]. ON therapies have 
been explored for mRNA down-regulation by antisense ONs [242–245] or siRNA [238,246]. 
Antibodies-based therapies are used to inhibit the PCSK9 ability to bind to the LDLR 
[247,248].  Moreover, recently, a new strategy includes the disruption of the gene by 
introduction of loss of function mutations by a clustered regularly interspaced short 
palindromic repeats (CRISPR/CRISPR-associated system [249].  
 
1.7 FRIEDREICH ATAXIA  
 
Friedreich ataxia (FRDA) is an autosomal recessive disease, characterised by progressive 
ataxia, spasticity, loss of lower limb reflexes, posterior column sensory changes, scoliosis, 
and foot deformity. 98% of the affected individuals are homozygous for a GAA trinucleotide 
repeat expansion in intron 1 of the FXN gene, and concomitant low levels of FXN gene 
expression [251]. FXN transcription inhibition can be attributed to multiple factors including 
disrupted transcriptional initiation or elongation and epigenetic changes affecting chromatin 
remodelling and DNA methylation [252]. The reduced expression of the encoded 
mitochondrial frataxin protein leads to deregulated iron metabolism, mitochondrial iron 
accumulation and increased cellular oxidative stress.  
Until now no treatments are available for FDRA. The length of the GAA repeats inversely 
correlates with the age of onset and directly correlates with the severity of the disease. The 
(GAA)n repeat is a mirror repeat DNA sequence that contains only purines on one strand and 
pyrimidines on the other strand. When subjected to negative supercoiling, the repeats can 
form intramolecular triple helix structures, generally called H-DNA [253].  
It is considered that expanded (GAA)n repeats form non-B DNA structures including 
intramolecular triplex structures (H-DNA) (Figure 8), and R-loops [254]. Several other 
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models have been proposed for alternative structures including the formation of a higher 
order structure named “sticky DNA”, which consists of an intramolecular triplex(es) likely to 
involve a pyrimidine-motif-triplex [255]. These structures seem to affect the stability of the 
repeat length as well as expression of the FXN gene and may prove to be associated with 
promoting epigenetic chromatin changes [256–258].  
 
 
Figure 8: Purine and pyrimidine H-DNA motifs formed at (GAA)n repeats.  
 
Therapies for FRDA are in development aiming either to revert the epigenetic changes 
associated with the disease, to increase Frataxin by supplementation of exogenous mature 
frataxin mRNA [259], to excise the repeats by ZFNs [260] or by (de)stabilisation of non-B 
DNA structures and R-loops that possible form at the repeats. Thus, histone deacetylase 
inhibitors were shown to increase Frataxin mRNA in FRDA mouse models and patient cell 
lines [255–258]; sequence-specific polyamides and low molecular weight minor groove 
binders enhanced Frataxin expression [253,261]; and recently Corey et al. reported increased 
expression of the frataxin gene by interfering with the R-loop formed at the (GAA)n repeats 
using LNA ONs in patient cell lines [262]. 
Regarding the triplex DNA, Bergquist et al. reported an increase in the proportion of the 
triplex formed at (GAA)115 repeats in plasmids in the presence of a ss(CTT)n DNA ON, 
suggesting stabilisation of the structure. However, the amount of triplex was not affected in 
the presence of the corresponding ss(GAA)n DNA ON [263]. 
All the work presented here and in the section 1.3.3, is the first proof-of-concept for each of 
these structures. Thus it would not be surprising to expect new developments in the field of 
non-B DNA-structure targeting in the future time. 
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2 AIMS 
 
This Ph.D. thesis aimed to develop and improve the applicability of ON therapeutics in 
different perspectives: 
 
I. Use of ON therapeutics as agents to modulate the proportion of two natural splice 
variants to regulate the gene expression and consequently the amount of active protein 
(Paper I). 
 
II. Development of new tools for screening ON chemistries and delivery vectors in a cell 
type dependent context (Paper II). 
 
III. Development and characterization of a new nucleic acid analogue with cell uptake 
properties independent of delivery vectors (Paper III and IV).  
 
IV. Evaluate the capacity of ONs to resolve non-B DNA structures in the genome, which 
are associated with gene silencing and consequently diseases (Paper V). 
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3 METHODOLOGY 
This section describes theoretical and practical aspects regarding the most relevant methods 
employed in the different papers presented in the thesis. A more detailed description of the 
protocols and additional methods can be found in the original documents. 
 
3.1 CELL CULTURE 
Cell lines are the gold standard of all “in vitro” experiments for biological studies, as well as 
screenings and development of drugs. Characterised by their simplicity, species-specificity, 
convenience and possibility for automation, they are simple models of complex biological 
systems as a whole organism, preceding the animal trials [264]. A cell line consists of a 
population of cells derived from a tissue of a multicellular organism, with the ability 
(acquired or induced) to proliferate indefinitely in culture and share a genetic profile among 
them. 
Different cell lines derived from human and mouse tissues were employed in this work. The 
human liver hepatocellular carcinoma cell lines HuH7 and HepG2 were used in the screening 
and activity evaluation of PCSK9 SSOs (Paper I). For the development of the new pLuc/705 
splice-switching reporter cell lines (Paper II) the HuH7, the human osteosarcoma U-2 OS, the 
mouse myoblast C2C12 and the mouse neuroblastoma Neuro-2a cell lines were chosen. In 
the study for determination of cell type efficiency characterization of already establish and 
new oligonucleotide chemical modifications and delivery approaches (Papers II and IV), the 
human cervix adenocarcinoma reporter cell line HeLa Luc/705 was used, together with the 
HuH7_705, U-2 OS_705, C2C12_705 and Neuro-2a_705 cell lines. For the evaluation of 
oligonucleotide cellular uptake by confocal microscopy (Paper III and IV), the U-2 OS cell 
line was the option. 
All cell lines were maintained and cultivated in Dulbecco's Modified Eagle Medium 
(DMEM, Life Technologies) high glucose, GlutaMAX™ supplemented with 10% fetal 
bovine serum (FBS, Life Technologies) at 37ºC, 5% CO2 in 95% humidity. For the new 
reporter cell lines, an additional supplementation of the medium with 400 or 200 µg/mL of 
Geneticin was made.  
 
3.2 ANIMAL EXPERIMENTS 
NMRI female mice with 20–22 g were used in the animal experiments in Paper I to access 
the splice-switching modulation ability of human sequence-specific PCSK9 SSO in vivo. The 
experimental protocol was approved by the Stockholm South Ethical Committee, according 
to the guidelines of the Swedish National Board of Laboratory Animals at Karolinska 
Institutet, permit number S48-12. The experiments were performed according to the ethical 
permission and designed to minimise the suffering and pain of the animals.  
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Mice, while anaesthetized, were treated with a 2 mL hydrodynamic infusion to the liver 
through the tail vein, or left untreated. Hydrodynamic infusion is a method known to result in 
preferential delivery to the liver and subsequent high expression [265,266]of the reporter 
plasmid. The infusion liquid consisted of a 0.9% NaCl solution containing 5 μg of reporter 
plasmid pLIVE.PCSK9.Luc together with either 0.7 mg/kg SSO or 3.7 mg/kg SSO. The next 
day, livers were carefully harvested post-mortem and snap-frozen for subsequent analysis.  
 
3.3 TRANSFECTION 
Transfection is the process by which natural or synthetic nucleic acids (e.g. plasmids, 
siRNAs, and oligonucleotides) are introduced into eukaryotic cells by non-viral methods 
[207]. The transfection efficiency is dependent on several conditions such as transfection 
media, cell type and density, nucleic acid concentration and the delivery method chosen 
[214,216]. Consequently, depending on the objective, several protocols can be followed. 
For the evaluation of the activity of PCSK9 SSOs (Paper I), cells were seeded the day before 
transfection, to have approximately 80% confluency (or 50-60% confluency for the starvation 
experiment) the next day. Transfection of the SSO constructs and the siRNA (positive 
control) was performed with Lipofectamine® 2000 (Life Technologies) or Lipofectamine® 
RNAiMax (Life Technologies), respectively and according to the manufacturer’s protocols. 
For the SSO constructs, a ratio of 2.5 µL of Lipofectamine® 2000 per 1 µg of SSO was used. 
The transfection complexes were left in the culture for 24 h, after which medium was 
changed, or cells were harvested. 
For the establishment of the stable reporter cell lines (Paper II), the cell lines, seeded the day 
before and at a 80% confluency, were transfected with 1.5 μg of the pT2Kole-Neo together 
with 0.5 μg of the pCMV(CAT)T7-SB100 vector with Lipofectamine® 2000 (Life 
Technologies) for HuH7 and U-2 OS cell lines, or Lipofectamine® 3000 (Life Technologies) 
for C2C12 and Neuro-2a cell lines following the manufacturer’s protocol. The plasmid 
constructs were used at a ratio of 2 µL of Lipofectamine® 2000 per 1 µg of plasmid, or a 
proportion of 2.2 µL of Lipofectamine® 3000 and 2 µL of P3000™ reagent per 1 µg of 
plasmid. Twenty-four hours post-transfection, the medium was removed, and new medium 
was added. Forty-eight hours post-transfection, the medium was changed to selection 
medium (DMEM plus 10% FBS supplemented with 800 μg/mL (HuH7, C2C12 and Neuro-
2a cell lines) or 600 μg/mL (U-2 OS cell line) Geneticin antibiotic (Life Technologies)) to 
initiate the isolation of monoclonal cultures. 
In the transfection of the reporter cell lines with SSOs by PepFect14 (Paper II), the cells were 
seeded the day before transfection, to reach approximately 70-80% confluency at the time of 
transfection. SSOs were mixed with PepFect14 at 5:1 molar ratios in nuclease free water in 
10% of the final treatment volume (i.e. 50 μL). Nanocomplexes were formed for 30 minutes 
at room temperature. Before the addition of the complex to the cells, the medium in the wells 
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was replaced with fresh medium (450 µL). The complexes were left in the culture for 24 h, 
after which cells were harvested.  
When the reporter cell lines were transfected with SSO by Lipofectamine® 2000 (Paper II), 
the same protocol conditions described for the Paper I (see above) were used.  
 
3.4 pLuc/705 SPLICE-SWITCHING REPORTER  
Developed by Kang et al. [267], the pLuc/705 splice switching reporter (represented by the 
reporter cell line HeLa pLuc/705) was fundamental in the development of the field of 
oligonucleotide therapeutics, and even today continues to be extensively used in the 
development of new nucleic acid analogues as well as delivery vectors. 
It consists of a luciferase-encoding gene interrupted by a mutated β-globin intron 2. The 
existence of this mutation (T→G in the position 705) of the intron creates an aberrant 5’ 
splice site that activates a cryptic 3’ splice site, resulting in aberrant splicing of luciferase pre-
mRNA and the translation of non-functional luciferase. When an SSO masks the aberrant 
site, splicing is redirected generating the correct mRNA, and consequently, the luciferase 
activity restored (Figure 9) [267]. 
 
 
Figure 9: Schematic representation of the pLuc/705 splice-switching reporter.  
 
This reporter was chosen for the development of the new stable reporter cell lines derived 
from muscle, neuron, liver and bone cell lineages (Paper II). The new reporter cell lines, 
named C2C12_705, Neuro-2a_705, HuH7_705 and U-2 OS_705, together with the well-
known HeLa pLuc/705, were further used for the characterization of nucleic acid chemical 
modifications, RNA analogues and delivery vectors (Paper II and IV). 
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3.5 GENE EXPRESSION ANALYSIS 
3.5.1 Reverse transcription-polymerase chain reaction (RT-PCR) 
RT-PCR is a variation of the polymerase chain reaction (PCR) commonly used for the 
analysis and quantification of mRNA expression. It comprehends the conversion of mRNA in 
a more stable cDNA by a reverse transcriptase enzyme, followed by exponential 
amplification of the target gene using specific primers flanking the region of interest. RT-
PCR can be performed in a one-step or a two-step reaction, and the final products can be 
quantified through two RT-PCR categories: endpoint (relative, competitive and comparative 
methods) or real-time (SYBR Green, TaqMan Probes, Molecular Beacon Probes) [268]. 
While both one-step (Paper I) and two-step (Paper I and II) reactions were used in the present 
work to amplify the different mRNA splice forms of PCSK9 and luciferase genes, in all cases 
quantification was obtained with end-point protocols and through the relative method.  
For a relative quantification the co-amplification of internal control is required, commonly an 
endogenous gene like the housekeeping genes HPRT (Paper I), GAPDH or 18S (Paper II). Its 
expression level should be unaffected by the experiment conditions, constant across all 
samples and the same cellular abundance as the target mRNA. This internal control serves to 
normalise the samples, after which a direct comparison of relative transcript abundances can 
be inferred among samples.  
The normal/alternative and correct/uncorrected splice products, as well as the endogenous 
control, were identified by their size using an agarose gel electrophoresis and band intensities 
were quantified using the QuantityOne Software (Bio-Rad).  
 
3.6 PROTEIN ANALYSIS 
3.6.1 Western Blotting 
Western Blotting is a semi-quantitative technique in cell and molecular biology that allows 
the separation and identification of proteins from a mixture, based on their molecular weight. 
After electrophoresis, the proteins are transferred to a nitrocellulose membrane, which is 
further incubated with proper primary and secondary antibodies to allow visualisation 
[14,269]. 
This technique was used in Paper I to quantitatively measure the increase of the PCSK9 
splice variant (PSCK9sv) and the LDLR, after cell treatment with SSOs.  
The membranes were scanned using the Odyssey Classic equipment (LI-COR) and 
fluorescence intensity of the secondary antibodies determined by the software Image Studio 
4.0. For quantification, the fluorescence intensities were plotted against the amount (μg) of 
loaded protein and the slope of the curves calculated by the method of least square. By this 
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approach, the slope of the curve, describing the regression between the fluorescence signal 
and the amount of protein loaded, reflects the concentration of the protein of interest.  
 
3.6.2 Luciferase assay 
Characterised by its sensitivity and linear response range, this bioluminescent assay is built 
on the enzymatic activity of firefly luciferase protein to oxidise D-luciferin in the presence of 
ATP, oxygen, and Mg
2+
, producing oxyluciferin and light, which can be measured by a 
luminometer [270]. This light quantitative output can then be correlated with the amount of 
firefly luciferase protein produced.  
However, to achieve greater confidence, data must be normalised before comparisons. 
Normalisation removes sample-to-sample variability caused by factors other than those being 
tested in the experiment, like variabilities in cell plating and transfection efficiency, pipetting 
inconsistencies, and toxicity [271].  Several methods can be used for normalisation, including 
normalisation to total protein content (can tighten the results and is the best option for stably 
transfected cells), total ATP content or cell number, and normalisation with a control reporter 
vector.  
 
3.7 TOXICITY ASSAYS 
Toxicity assays are necessary to identify potentially hazardous chemicals and to confirm, at 
earlier stages of development, the absence of certain toxic properties in new promising 
therapeutic drugs. They can involve tests to estimate the basal functions of the cell or tests 
specialised for specific cell functions [272]. The most common (and used) methods are based 
on the measurement of specific activities characteristic of viable cells. They include the use 
of different classes of colorimetric tetrazolium reagents, resazurin reduction and protease 
substrates generating a fluorescent signal, the luminogenic ATP assay, and a novel real-time 
assay to monitor live cells for days in culture [273].  
 
3.7.1 CellTiter-Glo® Luminescent Cell Viability Assay 
The CellTiter-Glo® Luminescent Cell Viability Assay (Paper I) is a method to determine the 
number of viable cells in culture based on the quantity of ATP present. ATP has been widely 
accepted as a valid marker of viable cells. This correlation relies on the fact that when the cell 
membrane integrity is lost, the cells lose the ability to synthesise ATP and the endogenous 
ATPases immediately degrade any ATP remaining from the cytoplasm [273]. 
The CellTiter-Glo® reagent is composed of a detergent (for lysing of cells), ATPase 
inhibitors (stabilisation of ATP released), luciferin (substrate), and the thermostable luciferase 
(Ultra-Glo™ Recombinant Luciferase) that catalyses the reaction where photons of light are 
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generated. This system has several advantages as being homogeneous (“add-mix-measure” 
protocol), fast (shorter as 10 minutes), more sensitive than colorimetric and fluorometric 
assays, less prone to artefacts, flexible and robust (luminescence signal very stable and half-
life of >5 hours). 
 
3.7.2 Cell Proliferation Reagent WST-1  
The Cell Proliferation Reagent WST-1 (Paper II) is a colorimetric assay to quantify the 
viability and proliferation in adherent or suspension cells. The reagent is a sterile, ready-to-
use solution, which contains WST-1 (tetrazolium salt) and an electron coupling reagent 
diluted in phosphate buffered saline. In contact with metabolically active cells, the WST-1 is 
cleaved by mitochondrial dehydrogenases to soluble formazan products. The formazan dye 
can be measured spectrophotometrically at wavelengths 420-480 nm. The absorbance 
measured can be directly correlated with the number of metabolically active cells [273]. This 
assay due to the high solubility of the dye is more convenient, more stable and less prone to 
artefacts and can be used for non-radioactive, spectrophotometric quantification of cell 
proliferation, growth, viability, and chemosensitivity in cell populations using the 96-well 
plate format. 
 
3.8 CONFOCAL LASER SCANNING MICROSCOPY FOR ON CELLULAR 
UPTAKE 
Developed around 40 years ago confocal laser scanning microscopy revolutionises the image 
acquisition of biological samples. The use of specific wavelengths of light (emitted from 
lasers), and the use of pinholes to eliminate out-of-focus light significantly increase the ability 
to resolve and co-localize small structures and molecules in high resolution and contrast 
images [274,275].  
However, this is not a straightforward technique, and there are ten important aspects to 
consider when using a confocal microscope, preparing a specimen, and handling digital 
images. First, the selection of optimal microscope components to eliminate physical factors in 
the design of microscopes that can result in image aberrations and can limit the resolution of 
pictures. Second, it is crucial to understand specimen fixation and processing, antigen–
antibody interactions, fluorescence theory (quantum efficiency, quenching, photobleaching). 
Third, the significant advantage of confocal imaging is the acquisition of high-resolution, 
high-contrast images obtained through the Z-axis of a sample, and the capability of software 
programs to reconstruct the 3-D nature of cells and tissues. Thus, during the processing, the 
integrity and the 3-D architecture of the specimen should be preserved as much as possible. 
Fourth, a good signal to noise ratio is fundamental. Fifth, quantification of fluorescence in 
confocal images is tricky, and they should be interpreted as semiquantitative analysis. Sixth, a 
thorough understanding of how the images are collected and processed by the system 
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hardware is critical. Seventh, always be very detailed in sample preparation, image collection, 
and in handling digital images. All these steps are crucial for obtaining images of high quality 
and with enough information for quantification. Eighth, ninth and tenth aspects focus on the 
acquisition, processing and storage of the original data. [274,275].  
Confocal laser scanning microscopy was used to evaluate the oligonucleotide cellular uptake 
(Paper III and IV). Briefly, U-2 OS cells were seeded at a density of 2x10
4
 cells per well in a 
175 μm glass bottom 96-well plate (Greiner Bio-One) the day before, to be 60% confluent the 
next day. The fluorescein labelled ONs were diluted in warm OptiMEM (LifeTechnologies) 
and added to cells after medium removal. After 8 h or 24 h of incubation, the cells were 
processed as follows: the medium was removed, cells washed once with warm Opti-MEM 
and stained with a 6.25 μg/mL solution of CellMask™ Deep Red membrane stain 
(LifeTechnologies) in Opti-MEM, 10 min, 37ºC. After staining, cells were fixed with warm 
4% paraformaldehyde, pH 7.4, in OptiMEM for 5 min at 37ºC, followed by three times 
washing with PBS. The cells were left in PBS and imaged immediately. Confocal laser 
scanning microscopy was performed using an Inverted Nikon A1R+ Confocal Microscope 
(Nikon Corporation, Japan) with Apo 60x oil λS DIC N2 objective (numerical aperture 1.4, 
refractive index 1.515) and galvano scanner. Pictures were acquired with the NIS-Elements 
Advanced Research Software (Nikon Corporation, Japan) using a pinhole size of 39.6 µm 
and Ti ZDrive performed the Z-stack bottom-to-top with approximately 0.2 µm/step. 
 
3.9 DNA STRUCTURE 
3.9.1  Triplex-directed DNA double-strand cleavage by BQQ-OP and primer 
extension assay 
A previous study on the formation of triplex structures at FRDA (GAA)n repeats show that a 
low-molecular weight benzoquinoquinoxaline compound (BQQ, Figure 10) recognises 
triplex structures formed at (GAA)n repeats in plasmids. BQQ is a DNA intercalating 
compound that specifically binds and stabilises triplex structures of both purine and 
pyrimidine motifs  [276–279]. BQQ is cell permeable and was shown to bind and stabilise H-
DNA structures formed in plasmids in growing Escherichia coli cells [280]. 
BQQ was further converted to a triplex-specific cleaving agent, Benzoquinoquinoxaline-
1,10-phenanthroline (BQQ-OP, Figure 10), by conjugation to a 1,10-phenanthroline derivate 
[277].  
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Figure 10: Chemical structure of benzoquinoquinoxaline (BQQ) and BQQ-1,10-
phenanthroline (BQQ-OP). 
 
Due to the combination of these two moieties, BQQ-OP can intercalate and cleave the double 
strand DNA specifically at the site of formation of a triplex (Figure 6). The reaction occurs in 
the presence of Cu
2+
 ions and a reducing agent, with the production of radicals in situ, which 
promoting dsDNA cleavage. BQQ-OP has been used to probe triplex formation including 
both H-DNA and TFO-directed triplex structures in plasmids in vitro [263,280]. 
The assay includes a two-step process (Figure 11) to analyse triplex formation in supercoiled 
plasmids.  
 
 
Figure 11: Schematic presentation of triplex-directed DNA double-strand cleavage by 
BQQ-OP. BQQ-OP binds to the H-DNA structure formed at (GAA)n repeats and causes 
dsDNA cleavage of the plasmid specifically at the triplex site, linearizing it. The following 
cleavage by a unique restriction enzyme of the plasmid yields two DNA fragments of specific 
sizes (X and Y) that can be resolved by electrophoresis. 
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First, the triplex site is cleaved by BQQ-OP linearizing the plasmid. The following cleavage 
by a unique restriction enzyme produces two DNA fragments of specific sizes, considering 
that the BQQ-OP cleavage occurs on average in the middle of the triplex. Agarose gel 
electrophoresis is used to resolve these two fragments, and the extent of the triplex-directed 
cleavage is calculated based on the intensity of the DNA bands, together with the remaining 
linear fragment. In the absence of triplex formation, only a linearized DNA fragment can be 
detected and quantified. 
BQQ-OP has used to evaluate the capacity of PNA and LNA oligonucleotides to disrupt 
higher order DNA structures in Friedreich’s ataxia (GAA)n repeats (Paper V).  
A primer extension reaction is used to map the 5ˊ ends of DNA (or RNA) fragments. It is 
performed by annealing a specific oligonucleotide primer, usually radiolabelled at 5' end, to a 
position downstream of the 5ˊ end to be mapped. It is followed by DNA polymerase 
extension, where the DNA template is copied, and produces a fragment that ends at the 5' end 
of the template molecule. Analysis of primer extension of the extended DNA products is 
done on denaturing polyacrylamide gels and autoradiography. 
Primer extension reaction was used to analyse the products of triplex-directed DNA cleavage 
by BQQ-OP (Paper V). The objective was to detect the nucleotides that are involved in a 
triplex structure. To achieve a detailed analysis of the triplex-directed cleavage of plasmids 
by BQQ-OP, each of the (GAA)n or (CTT)n containing strands were used as template in 
separate reactions. In this case, the radiolabeled primers bind to the flanking regions of the 
triplex forming sequence. Normally, the polymerase reaction would stop at the cleavage site 
on the DNA template and the fragments analysed. However, structures that may form within 
the DNA sequences will influence the extension reaction and may cause pausing of the 
polymerase. Consequently, the DNA template is linearized by a restriction enzyme to prevent 
structural formation and reduce pausing. Still, a background pausing is often present, which 
reinforces the importance of strong negative controls. 
 
3.9.2 Atomic Force Microscopy (AFM) 
Electronic microscopy (EM) has been the only analytical tool for analysis of the structure of 
biomolecules that are too complex for X-ray and NMR and too small for optical microscopy. 
Besides presenting high power and versatility, it lacks the ability to analyse structures under 
conditions closely resembling their physiologic environment [281]. Atomic force microscopy 
(AFM) emerges as a way to overcome this problem, since it can operate in air or liquid, being 
the only microscope that can achieve nanometer resolution on biological samples under 
physiological conditions. These instruments use a sharply pointed sensor, or “tip”, mounted 
on the end of a flexible cantilever. As the sample is scanned beneath the tip, small forces of 
interaction with the sample cause the cantilever to deflect, thereby revealing the sample 
topography [281,282]. 
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The AFM imaging acquisition from contact mode to Tapping Mode™ and to Peak Force 
Tapping™ reduced the damage of the specimen drastically, allowing the imaging of soft 
polymers, lipid bilayer, proteins, DNA, and whole cells. Furthermore, PeakForce® tapping 
mode, where the applied force can be controlled and decreased below the nano-Newton 
range, allows the analysis in liquid, an advantage compared to traditional Tapping Mode™ 
[283]. The possibility to perform scans in liquid is extremely advantageous for imaging 
unfixed biological samples near to physiological conditions [283]. However, measurements 
in liquid require crucial aspects in sample preparation, especially for DNA specimens.  
It could be assumed that physiological condition buffers, containing Mg
2+
 and Na
+
, both 
required for DNA structures stabilisation, would be enough for visualisation of DNA 
[283,284]. While Mg
2+
 binds very weakly to mica surfaces, the presence of Na
+
 promotes the 
release of DNA molecules from the surface.  This salt effect can be overruled by the addition 
of Ni
2+
 ions to the buffer. The optimal Ni
2+
 concentration should permit an “ideal” attachment 
of DNA to the mica surface, avoiding Ni
2+
 precipitation and poor DNA binding, which 
normally occurs at higher and lower NiCl2 concentrations, respectively [285,286]. 
Additionally, studies by Billingsley et al. (2010) demonstrate that the hydration of the sample 
during AFM measurements is crucial to determine the morphology of supercoiled plasmids. 
They show that supercoiled samples prepared with Ni
2+
 with high hydration are more 
condensed, with a large number of crossovers, local conformation changes, and more turns 
effects that seem to be topologically driven. They also postulate that under these conditions, 
the configuration is closer to the 3D biological shape [287].  
PeakForce® Tapping measurements in liquid (Paper V) were performed on an atomic force 
microscope (Dimension Fast Scan, Nanoscope V, Bruker®, Santa Barbara, CA) located in 
the AlbaNova Nanofabrication Facility (Stockholm, Sweden). In these type of measurements, 
the scanner vibrates at a low frequency (1-3 kHz), resulting in a tip-sample interaction with 
every oscillation. The maximum force applied on the tip was decided and kept constant with 
a feedback loop, which adjusts the overall extension of the piezo during scanning and allows 
non-destructive topography imaging [285,288,289]. In this study, the AFM images were 
obtained using silicon nitride cantilevers with silicon tips (ScanAsyst-Fluid+, Bruker®, Santa 
Barbara, CA) with a nominal tip radius of 2 nm and spring constants ranged between 0.4 and 
0.7 Nm
-1
. The images were obtained with scan rates between 1 and 1.5 Hz, the maximum 
force of 500 pN, scanner oscillation amplitudes between 60-40 nm, scanner resonance 
frequency of 2 kHz, the image resolution of 512 x 512 pixels and scan sizes around 5 x 5 and 
1.3 x 1.3 µm2. In all images, the vertical limit was reduced to 1 µm to enhance the resolution. 
Plasmid areas from all scans obtained were calculated by Image J software and GraphPad 
Prism 6 software performed statistical analysis. 
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4 RESULTS AND DISCUSSION 
 
4.1 Paper I 
RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. 
In this paper, we aimed to develop a new approach to inactivate PCSK9, through conversion 
of the normal splice form to a natural, less abundant and inactive, splice variant (PCSK9sv) 
by splice-switching oligonucleotides (SSOs). 
The rationale here emerged from the publication of  Schmidt et al. [239] describing PCSK9sv 
(splice variant lacking exon 8) (§ 1.6) and by the fact that SSOs were previously never used 
for regulation of gene expression by changing the alternative splicing pattern of available 
biological isoforms, without creating aberrant transcription forms. 
Thus, several SSOs sequences targeting different regions in the exon 8 of the human PCSK9 
gene were designed based on the data retrieved from three predictive ESE and ISE 
bioinformatics programs. We choose to synthesise the SSOs as fully 2ˊ-OMe PS ONs since 
this is a chemical combination commercially available, transfection protocols are well 
characterised, and several studies show that they are efficient in splice modulation approaches 
and accumulate preferentially in liver and kidney. 
The initial SSO screening and determination of effective SSO concentrations were initially 
performed in HuH7 cell lines, and the best candidates were further tested in HepG2 cell lines 
to evaluate if the effect is cell line specific. The expression of PCSK9 full length (PCSK9fl) 
and PCSK9 splice variant (PCSK9sv) were quantified by RT-PCR and normalised to HPRT 
mRNA. The primers were located near the extremities either on 3ˊ-end of exon 7 or 5ˊ-end of 
exon 9 to allow size discrimination between the two isoform products. We found a significant 
reduction of the wild-type form in both cells lines for all treatments as compared to non-
treated cells (P<0.05 and P≤0.01). Regarding the formation of the PCSK9sv, both cells lines 
show statistically significant difference between hP872 treated and non-treated groups. 
Together these results indicate that splice modulation was not cell line specific and that the 
best performing SSO was hP872 at a concentration of 100 nmol/L. 
To evaluate potential toxic effects, the viability of the cells upon SSO treatment during 24 h 
was then measured, with no variation in viability observed for both cell lines. This 
experiment was also important to demonstrate that changing the proportion between the two 
isoforms does not affect cell metabolism. 
Next, we aimed to evaluate the treatment in a more metabolic/biological context.The PCSK9 
expression is known to be regulated by the levels of cholesterol in the medium, and Medina et 
al. showed that the addition of cholesterol after a period of sterol starvation increases the full-
length isoform of PCSK9, while it decreases the splice variant [290]. Consequently, the best 
way to challenge our therapeutic approach would be by confirming that the splice modulation 
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could remain after a period of cholesterol depletion/addition. For this purpose, Huh7 cells 
were treated with the SSO hP872 at 50 and 100 nmol/L for 24 h, after which, a period of 
cholesterol depletion, was induced for 24 h, followed by the addition of 20 nmol of 
cholesterol. The levels of total, full length and spliced PCSK9 mRNA were measured after 
this treatment (57 h post transfection). A statistically significant difference (P<0.0001) is 
found among all treatments, and a clear reduction of the levels of the total and full-length 
mRNA can be observed when the cells are treated with hP872 at 100 nmol/L (P=0.006 and 
P<0.0001). This was also confirmed at the protein level. Concomitant with an increase in the 
PCSK9sv splice form, a decrease in the pro-protein form is observed when the cells are 
treated with the SSOs.  Additionally, the data shows that, after treatment, the splice variant 
did not decrease as quickly as the full-length form, and its amount is significantly higher 
when compared to non-treated cells. This finding proves that our approach can persist against 
specific splice regulators and confirm the efficiency of the strategy.     
To examine the biological relevance of our approach, and if an increase in PCSK9sv 
mediated by SSOs would enhance LDLR protein levels, we analysed the levels of LDLR 
protein in the samples of the cholesterol depletion/addition experiment. As expected, an 
increase in LDLR levels is observed, especially when cells are treated with SSO hP872. This 
final data confirm, without a doubt our hypothesis. 
Once we had the proof of concept, another hypothesis arose. Is this approach also efficient in 
vivo? For this experiment, some aspects had to be taken into account. First, preliminary 
studies had shown that mice specific SSOs against the same sequence did not show any 
significant effect on the formation of the splice form. Altogether, our data suggests that this 
mechanism is human-specific. Second, we did not have access to relevant mice models to test 
our hypothesis.  
To assess the human sequence-specific SSO in vivo a liver-specific luciferase reporter vector 
containing the genomic sequence of the human PCSK9 including exon 7 to exon 9 was 
created, pLIVE.PCSK9.Luc. Additionally, the NMRI mouse strain was used since is 
considered to be the experimental animal that best mimics a human population and thus being 
used in many fields of general biology, in pharmacology and toxicology studies.  
The mice were co-injected with the reporter plasmid and the SSO hP872 or CTR SSO by 
hydrodynamic infusion. The expression of the vector was verified by luciferase mRNA. The 
results show complete conversion to the splice form when SSO hP872 is present, while for 
CTR SSO both the full mRNA (PCSK9_E7-9) inserted and the splice form (PCSK9_E7-9Δ8) 
are detected. The effect was also concentration dependent. We also analysed the expression 
of endogenous pcsk9, and no significant changes are found, proving the specificity of our 
SSO for the human sequence. 
Altogether, our data showed that PCSK9 activity could be modulated by splice-switching 
through a human specific RNA therapeutic approach and the adjustment of the natural active 
to non-active isoform represents a physiological way of regulating the cholesterol 
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metabolism, by controlling the amount of LDL receptor available and the rate of LDL-
cholesterol clearance. 
 
4.2 Paper II 
Four novel splice-switch reporter cell lines: distinct impact of oligonucleotide chemistry 
and delivery vector on biological activity. 
In this paper, we aimed to develop a small “tissue” library of new stable pLuc/705 splice-
switching reporter cell lines that will allow determination, if any, of the cell type dependence 
in the biological activity of ON chemistries and delivery vectors.   
Despite the new advances in the ON field, a clear knowledge regarding how certain 
chemistries behave alone, or in combination with various delivery vectors, is still limited 
[291]. Their characterization is frequently restricted to a single reporter cell line and, when 
different cell lines are studied, the experimental conditions differ. Aware of this, we decided 
to create four new monoclonal stable reporter cell lines derived from muscle, neuron, liver 
and bone cell lineages carrying the pLuc/705 splice-switching reporter (§ 3.1 and 3.4). These 
cell lines, together with the already existent HeLa Luc/705, will constitute a tissue library for 
evaluation of new SSO chemistries and delivery vectors that allow a cell-type dependent fair 
comparison.  
Accordingly, several monoclonal for HuH7_705, U-2 OS_705, C2C12_705 and Neuro-
2a_705 cell lines were established (§ 3.1), expanded, selected based on the lower levels of 
endogenous splice correction and higher SSO-induced splice correction and characterised. 
Our data shows that in contrast to the previous HeLa Luc/705 cells, a slightly higher 
endogenous level of correctly spliced mRNA is observed in the different cell lines, but these 
values are similar through several passages of the cultures, demonstrating the robustness of 
these reporters. Equally, the total amount of luciferase mRNA is also lower, presumably as a 
consequence of the transposase-based approach employed here, which limits the number of 
insertions into the genome. The morphology of the new reporter cell lines is similar to the 
parental cell lines and their culture doubling times are approximately 19, 34, 28 and 21hours 
for C2C12_705, U-2 OS_705, HuH7_705 and Neuro-2a_705, respectively.      
In order to evaluate if the influence of the ON chemistry and/or the delivery vector on the 
biological activity is cell type-dependent, all the new reporter cell lines together with the 
already existent HeLa Luc/705 reporter were either transfected with SSOs (2ˊ-OMe PS, 2ˊ-
OMe/LNA PS and 2ˊ-OMe-ZEN PS) (§ 1.4.1, § 1.4.2) together with Lipofectamine® 2000 (§ 
1.5.1), treated with PepFect14 nanoparticles (§ 1.5.2), or assayed for ‘naked’ ON uptake in 
Ca
2+
 enriched medium. Treatments were performed with two (and three in the naked 
approach) different concentrations, and both mRNA as well as luciferase production were 
analysed.  
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To exclude toxicity effects derived from the treatments, cytotoxicity for all the formulations 
used was evaluated, and no adverse effects were observed in any of the cell lines. 
Additionally, SSO formulation efficiency could be dependent on the size and number of the 
particles formed, and different chemistries can formulate differently. To determine if the 
effects would be chemistry/vector-dependent, particle size determination by nanoparticle 
tracking analysis was performed for all the formulations. No significant differences due to 
SSO chemistry were found between the size or number of particles for either delivery vector. 
Excluded effects in toxicology and formulation, the readout should be mainly dependent on 
SSO chemistry. Previous reports in HeLa Luc/705 and confirmed in our Lipofectamine 
experiments, would dictate that with this delivery vector, the 705_ZEN SSO should be more 
potent than the 705_LNA SSO, followed by the 705_2ˊ-OMe SSO. However, our 
observations clearly showed that depending on the cell line, different ON chemistries in a 
lipoplex context or PepFect14 nanoparticles show various activities.  
Comparison of lipid-assisted with peptide-mediated delivery revealed that the 705_LNA SSO 
did not display any cell type variation in its activity (better in both cases in U-2 OS_705 > 
HeLa Luc/705 > Neuro-2a_705 > C2C12_705 > HuH7_705). In contrast, a cell type-specific 
pattern is found with the 705_2ˊ-OMe SSO. Both delivery approaches show higher activity in 
U-2 OS_705; but then, for Lipofectamine® 2000, HeLa Luc/705 > Neuro-2a_705 cell lines, 
while for PepFect14, the second best is in the C2C12_705 cell line. Surprisingly, whereas the 
705_ZEN SSO is the best SSO in all cell lines when delivered using the cationic lipid 
reagent, its activity is very low (U-2 OS_705 and C2C12_705) or negligible using PepFect14 
nanoparticles. The reason for this variability remains unknown and requires further study. 
Cell line dependence of different chemistries is also found in ‘naked’ uptake. The 705_LNA 
SSO is more efficient in cell lines considered as poor in ‘naked’ uptake, like HeLa Luc/705, 
Neuro-2a_705 and C2C12_705, while the 705_2ˊ-OMe and 705_ZEN SSOs perform better 
in cells like HuH7_705 and U-2 OS_705. Our data is in agreement with the in vivo findings 
for low activity of 705_ZEN in muscle cells upon naked systemic delivery of the SSO. Most 
interesting is the low activity of SSOs like 705_LNA and 705_ZEN in the HuH7_705 
hepatocyte cell line, leading us to postulate that the higher activities normally observed for 
these SSOs in vivo in liver could be a consequence of the high vascularization of this organ or 
the profound fenestration rather than a sign of cell specificity or other fundamental 
differences between primary hepatocytes and this laboratory adapted cell line. 
In conclusion, we successfully establish a new tissue library of reporter cell lines. Through 
them, we demonstrate that the biological effect of ONs is dependent on the particular 
chemical modification as well as on the delivery vector, both activities being cell line 
dependent. Thus we believe that these new cell lines have high potential as models for cell 
type-specific screening in the ON field. Additionally, the biological effect can be easily 
evaluated by RT-PCR or by a Luciferase assay, allowing for high-throughput analysis. 
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4.3 Paper III 
Nuclease resistant oligonucleotides with cell penetrating properties. 
In this paper, we report the synthesis and characterization of ONs modified with a new 
nucleic acid chemical analogue 2ˊ-O-(N-(aminoethyl)carbamoyl)methyl (2ˊ-O-AECM) 
adenosine. 
The groundwork started in the lab of Prof Roger Strömberg with the synthesis of the first 2ˊ-
O-AECM adenosine analogue and the formation of 2ˊ-O-AECM adenosine dinucleotides 
[292]. It was shown that the 2ˊ-O-AECM moiety, to an even greater extent than the 
carbamoylmethyl (CM) modification [35], protected the dinucleotide against enzyme-
catalysed degradation by snake venom phosphodiesterase I, and made it completely resistant 
to degradation by spleen phosphodiesterase II.  
The question if 2ˊ-O-AECM ONs could be synthesised, and what properties they would have, 
was raised based on the high nuclease resistance shown by the 2ˊ-O-AECM dinucleotides, 
together with a study showing that ONs containing the N-((N,N-dimethylaminoethyl) 
carbamoyl)-methyl modification could form RNA duplexes with higher melting 
temperatures. 
This work started with the synthesis of 2ˊ-O-AECM adenosine containing ONs with several 
lengths (17, 16 and 13-mer), number and position of the modifications. This ONs were 
further evaluated for stability, type of interaction and conformation in the context of RNA or 
DNA duplexes. The results show a general increase in the thermal melting of the complexes 
RNA (+0.5 to +2.3 degrees per modification), while in complexes with DNA there was little 
difference (-0.3 to +1.0 degrees per modification) compared to a DNA-DNA duplex. 
Additionally, the slightly thermal melting increase observed for 2ˊ-O-AECM:DNA is mainly 
due to electrostatic interactions, while for 2ˊ-O-AECM:RNA  the stabilisation is not only an 
electrostatic effect, but additional factors could stabilise de duplex. Structurally, the 
incorporation of the 2ˊ-O-AECM modification forces the duplex (with DNA or RNA) to 
adopt an A-conformation, which is consistent with the higher melting temperature. Moreover, 
the stability to nucleases was also evaluated by incubation with 90% human serum. HPLC 
data showed that after 24h, the 13-mer fully modified 2ˊ-O-AECM ON was still intact.  
Cellular uptake of ONs without the addition of transfection agents is rare. As discussed 
before, CPP-ONs conjugates (§ 1.5.2), due to the positive charge of the peptide moiety, can 
efficiently be delivered to cells. The 2ˊ-O-AECM modification also possesses a positive 
charge, resembling a cell penetrating oligonucleotide (CPO), raising the question if they will 
be freely taken up by cells. 
In that respect, a 10-mer 2ˊ-O-AECM adenosine ON fluorescein labelled was synthesised and 
tested for naked cellular uptake in U-2 OS cells at 8µM. Confocal microscopy analyses 
showed an efficient cellular uptake after 8 h incubation. However the spotted appearance 
could indicate that most of the material was still entrapped in the endosomes.     
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Our results show the successful synthesis of 2ˊ-O-AECM adenosine containing ONs, which 
demonstrate a positive effect on the thermal melting of duplexes with RNA, resistance to 
degradation in human serum and cellular uptake without any additives, such as cationic lipids 
or cell penetrating peptides. 
 
4.4 Paper IV 
Fully and partially AECM-modified oligonucleotides. Synthesis and initial studies on 
cellular uptake and splice-switching activity in different reporter cell lines. 
In this manuscript, we aimed to evaluate the potential of 2ˊ-O-AECM modifications in fully 
and partially modified ONs as splice-switching therapeutic agents. 
The interesting findings from Paper III lead us to further explore the 2ˊ-O-AECM 
modification in a biological context. The development of the new reporter cell lines from 
Paper II, together with the existent reporter cell line HeLa Luc/705, dictated the biological 
approach and the ONs sequences to be used here.   
The 705 SSO has a mixed sequence, including all four nucleotides. Since our previous report 
on 2ˊ-O-AECM modified ONs only involved the adenosine monomer, the synthesis of 2ˊ-O-
AECM guanosine, uridine and cytidine building blocks were developed. The synthesis of the 
18-mer fully 2ˊ-O-AECM modified ON (ON1) and its derivatives also required synthesis 
improvements. The ON1 was analysed regarding the target mRNA, showing an increase in 
melting temperature of 0.4ºC per modification, which is similar to the value of a 2ˊ-OMe PS.  
Further studies, as compared to Paper III, to verify the influence of the 2ˊ-O-AECM 
modification on cellular uptake using confocal microscopy were done. Thus the synthesis of a 
series of fluorescein-labelled fully modified ONs of various length, ONs incorporating a mix 
of 2ˊ-O-AECM and 2ˊ-O-Me groups, and ONs with a combination of 2ˊ-O-AECM/ 2ˊ-O-Me 
PS or 2ˊ-O-AECM PS/ 2ˊ-O-Me PS chemistry was performed. Similarly as in Paper III, also 
the U-2 OS cell lines were used, but the ON concentration was reduced to 4 µM and two-time 
points tested, 8 and 24h. The changes in the protocol were made to verify if the same 
behaviour would be observed at lower concentrations (8 µM is not a desirable concentration 
for naked uptake).  
Confocal microscopy analysis revealed that the 2ˊ-O-AECM modified ONs clearly have the 
ability to be taken up by cells, in the absence of transfection agents, and that this 
internalisation is ON size- and modification-degree dependent. The data from the combined 
ONs (AECM, PS and 2ˊ-OMe), showed that after 8h the positive control (fully 2ˊ-OMe PS 
ON) showed high cellular internalisation, some nuclear localisation and a more diffuse 
pattern, while the 2ˊ-O-AECM containing ONs showed lower uptake and appeared to have 
higher endosomal localisation. No significant changes were observed between the 2ˊ-O-
AECM containing ONs. Additionally, at 24 h, an increase in the uptake was observed for all 
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ONs. Data show that the fully 2ˊ-OMe PS ON has a nuclear localisation exclusively. On the 
other hand, AECM modified ONs showed a relation between the increase in uptake and 
nuclear localisation, with an increasing amount of PS backbone linkages. This data set 
suggests that the incorporation of PS backbones improves the uptake and cellular distribution 
of 2ˊ-O-AECM modified ONs. Notwithstanding, the comparison between the two-time points 
seems to indicate that a different uptake mechanism for the AECM modification may also be 
involved. Also and as previously reported for PS ONs, 2ˊ-O-AECM modified ON 
internalisation and distribution within cells can also be time, temperature, concentration and 
cell line dependent. 
To assess the splice-switching activity, several ONs containing AECM modifications were 
synthesised and tested: fully AECM; combined 2ˊ-O-AECM/2ˊ-O-Me; combined 2ˊ-O-
AECM/2ˊ-O-Me oligonucleotides with complete PS backbone; and combined 2ˊ-O-
AECM/2ˊ-O-Me with partial PS backbone. The splice-switching activity was evaluated in the 
new reporter cell lines (C2C12_705, HuH7_705, Neuro-2a_705 and U-2 OS_705) (Paper II) 
in parallel with the commonly used HeLa Luc/705 [267] and with a calcium-supplemented 
protocol [293] at 1 or 4 µM after 72 h. The splice-switching activity was measured by 
luciferase readout.  
The data show no significant increase in the luciferase levels for all ONs in the “difficult to 
transfect” C2C12_705 cell line. So, additional measures are needed for efficient splice-
switching in this cell line, as also showed in the Paper II. Regarding the other cell lines, a 
statistically significant concentration-dependent increase of the luciferase levels was found 
for AECM containing ONs. For the hepatocyte HuH7_705 and the cervix HeLa Luc/705 cell 
lines, a higher spice-switching activity was found with the 2ˊ-OMe PS ON, while significant 
splice-switching was found with AECM containing ONs, especially for fully AECM 
modified ON. Based on the results, for these cell lines, neither replacement of AECM 
nucleosides with 2ˊ-O-Me nucleosides or introduction of PS adds any benefit regarding the 
activity. The same is true with the Neuro-2a_705 cell line, where especially the fully AECM 
modified ON and the partially PS/partially 2ˊ-O-Me ON displayed a similar activity as the 2′-
OMe PS ON.  
It is interesting to see that with U-2 OS_705 cells, although all ONs show significant activity 
there is a beneficial effect of adding PS to the backbone of AECM oligonucleotides. This is 
consistent with the increase in cellular uptake in U-2 OS cells observed by confocal 
microscopy. However, the similar splice-switching activity of the 2ˊ-OMe PS ON and the 
AECM oligonucleotide with the partial 2ˊ-O-Me and full PS modification ON, at higher 
concentration, is not quite consistent with the confocal data. Here, the 2ˊ-OMe PS ON gives a 
somewhat higher uptake. This can be possibly explained with the different time points, 24 
versus 72 h, used for the confocal experiments and the splice-switching assays. Confocal 
experiments seem to indicate that the uptake kinetics could be somewhat slower for the 
AECM ONs than for the 2ˊ-OMe PS ON, but there are also substantial differences in the 
experimental conditions.  However, both experiments support the conclusion that 
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incorporation of PS in the AECM oligonucleotides is beneficial in U-2OS cell lines. 
However, for the other cell lines tested, this effect was not observed.  
The ONs Tm when hybridising with the target mRNA were also measured. No indication of 
the Tm values of the ONs can explain the differential effect on the splice-switching activity. 
This indicates that the different activities may be cell type dependent or due to intracellular 
availability/uptake of ONs, rather than to their affinity for the target.  
In conclusion, we showed that AECM modified ONs could be synthesized and combined 
with previously established chemical modifications. We confirmed that 2ˊ-O-AECM 
modified ONs clearly have the ability to be taken up by cells, in the absence of transfection 
agents. We also found that 2ˊ-O-AECM modified ONs can act as splice-switching ONs in 
several cell lines (HuH7_705, HeLa Luc/705, Neuro-2a_705, U-2 OS_705 or C2C12_705).  
 
4.5 Paper V 
Disruption of higher order DNA structures in Friedreich’s ataxia (GAA)n repeats by 
PNA or LNA targeting. 
In this work, we aimed to disrupt using sequence specific PNA oligomers or LNA ONs, the 
non-B DNA structure(s) formed at the (GAA)n repeats in the FXN gene and associated with 
Friedreich’s ataxia. 
This work emerged as a continuation of the report from Bergquist et al., in which it was 
demonstrated that CTT DNA TFOs bind dsDNA at GAA repeat sequences forming a 
pyrimidine motif triplex. Conversely, purine motif triplex formation was not detected at this 
site when using the corresponding GAA TFO [263]. Additionally, it was also demonstrated 
that binding of a single strand CTT ON to the H-DNA forming plasmid enhanced triplex-
formation significantly, whereas an analogous GAA ON had no such effect. 
Knowing the high capacity of PNAs to form triplex structures, we decide to test if PNA 
would behave differently when targeted to FRDA expanded GAA repeats. PNA oligomers 
consisting of CTT or GAA repeat sequences were used. Triplex formation by PNA oligomers 
was examined using a triplex-specific dsDNA cleavage reaction mediated by BQQ-OP (§ 
3.9.1) in linearized plasmids to avoid intrinsic H-DNA formation. 
The data show that binding of CTT-PNA (in presence or absence of Mg
2+
) followed by BQQ-
OP dsDNA cleavage resulted in the formation of two DNA fragments having the expected 
sizes indicating the formation of a triplex. In contrast, binding of GAA-PNA shows only a 
single DNA fragment exhibiting slightly slower gel mobility than the linearized plasmid, 
which can indicate stable PNA binding to the dsDNA plasmid, maybe due to the formation of 
a duplex invasion complex. Based on these observations and that the triplex formed by CTT-
PNA binding resulted in a clear BQQ-OP cleavage, we conclude that a purine motif triplex is 
not formed in the presence of GAA-PNA. 
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Similarly, binding of CTT and PNA oligomers to FRDA repeats in supercoiled pMP179(115 
repeats) was performed. Binding of CTT-PNA to the (GAA)115 repeat leads to statistically 
significant increase of the amount of triplex, Interestingly, when a GAA-PNA oligomer is 
used, there is no detectable triplex-containing structure, including H-DNA. Only one major 
DNA fragment was observed upon BQQ-OP treatment, corresponding in size and gel 
mobility to the linearized plasmid. It is worth noting that a slower mobility band is detected in 
the sample containing the (GAA)115 repeat plasmid and GAA-PNA indicating a stable 
interaction, which we believe can be attributed to a sequence-specific GAA-PNA binding to 
the repeats region. Our data shows that binding of a GAA-PNA oligomer to FRDA repeats 
has the unique ability to completely abolish all triplex structures, which are detected by BQQ-
OP, including H-DNA, under these conditions. 
To clarify the interactions observed previously for the PNA oligomers, structural analysis was 
performed using either chemical modification of ssDNA regions by chloroacetaldehyde 
(CAA) or BQQ-OP mediated cleavage of DNA triplex structures followed by primer 
extension assays. Two different supercoiled plasmids carrying short or medium (GAA)n 
repeats (n=9 or 75, respectively) and including FRDA flanking sequences were used.  
Characterization of the structure at the shorter GAA repeat showed two different H-DNA 
pyrimidine motif triplex structures with the 5ˊ3ˊ3ˊ H-DNA isomer as the predominant isomer. 
Binding of CTT PNA is compatible with the formation of a triplex invasion complex of two 
CTT-PNA oligomers binding to the R-strand at the (GAA)9 repeat. On the other side, binding 
of GAA PNA showed a clear formation of a single strand region throughout the R-strand and 
is therefore ascribed to a GAA-PNA duplex invasion of the repeat region. 
Regarding the characterization of the medium GAA repeat, we could only detect the of 
formation of a 5ˊ3ˊ3ˊ- pyrimidine H-DNA. In this case the chloroacetaldehyde modification 
of the longer repeat failed to reveal bands that could indicate the presence of non-base paired 
nucleotides in either of the R- or Y-strand, suggesting the presence of more complex higher 
order DNA structures and indicating a difference between the pathological and normal repeat 
lengths. Binding of CTT PNA suggests three different modes of interaction: CTT binds to the 
single-strand region in the H-DNA, formation of a triplex invasion complex of two CTT-
PNA oligomers (consisted with the 9 repeats data) or triplex formation. The GAA PNA data 
showed, as for the 9 repeats, a simple strand invasion. 
Based on these results it is clear that PNA oligomers can interact with H-DNA formed at the 
(GAA)n repeats and while CTT PNA stabilises this structure GAA PNA seems to disrupt it.  
To examine whether another type of modified oligomer, with comparable dsDNA invasion 
properties as PNAs, could mediate results similar to those previously observed, the BQQ-OP 
cleavage assay was performed in the presence of CTT- or GAA-LNA-PS oligomers. The 
results show that in the presence of GAA LNA ONs the amount of H-DNA is almost not 
detectable, in contrast to the treatment with a 12-mer CTT LNA oligonucleotides. This results 
support the hypothesis that modified GAA ONs can be used to destabilise triplex structures 
formed at (GAA)n repeats. 
DNA topology is affected by the formation of higher order DNA structures not the least at 
expanded triplet repeats. Atomic force microscopy (AFM) has been used to examine 
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cruciforms, H-DNA and higher order structures at CAG and GAA repeats, respectively. In a 
similar way, we reasoned that oligomer binding to structure forming GAA expansions should 
be reflected by changes in DNA topology (and thereby morphology of circular DNA) and 
could be detectable by AFM. To examine this hypothesis, we monitored the effects of LNA 
binding to pMP179(115 repeats) using CTT-, GAA- or a scrambled-LNA (§ 3.9.2). 
The results showed clear changing in the plasmid morphology when GAA oligonucleotides 
were present, acquiring a more relaxed morphology when compared to non-treated plasmid 
or controls. To our knowledge, this was the first time that a plasmid of this size and 
characteristics was analysed by AFM in liquid. 
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5 CONCLUDING REMARKS AND FUTURE PERSPECTIVE 
The development of new technologies and approaches for ON therapies are the main focus of 
the present thesis.  
This work contributes to the field of ON therapeutics by an emphasis on the major challenge 
that is the delivery. First, the reporter cell lines developed will enable the chance to 
characterise chemistries and vectors in cell types for which reporters were not previously 
available. Determining which chemistry is suitable for different cell types will allow the 
development of new therapeutical approaches with the potential of organ targeting.  
The new nucleic acid analogue with cell penetrating properties has the potential to facilitate 
the delivery of ONs in the naked form, i.e. without the needed for delivery vectors. However, 
further studies are required until the full potential of this chemistry is unravelled. 
We also present two different approaches for gene regulation, namely at the RNA and at the 
DNA level. While promising, the full therapeutic potential for hypercholesterolemia using 
RNA splice-modulation of the two isoforms of PCSK9 is not known. More studies are 
needed in relevant animal models. However, in theory, this approach represents a novel 
concept, which could either stand-alone or serve as a complement to other cholesterol-
reducing treatments. 
The first steps for targeting non-B DNA structures formed at the GAA repeats with ONs have 
been taken. To reveal their full potential studies need to be carried out in a more relevant 
biological context. Under the conditions used, i. e. in vitro, outside cells, PNA seems to be 
more efficient than LNA; however, in a biological context, LNA may prove to be better, 
because of its more favourable uptake into cells. Recent developments in technologies for 
PNA delivery may selectively promote the uptake. Further studies are needed to develop this 
concept into a more physiological approach.  
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